Message from the CNSF President

Dear all,

We look forward to seeing you in Toronto, May 20-26, at the Fairmont Royal York Hotel. The annual Congress is jammed with new content and learning opportunities, combined with presentations of new clinical science. This year, we have a special collaboration with the University of Toronto, Division of Neurosurgery as they celebrate their 100th anniversary. There will be time to re-connect and re-establish old friendships. Many thanks to Joe Megyesi who chairs the Scientific Program Committee and continues to produce excellent programming. 2024 Congress materials, i.e. Program, Session outlines and course notes, are all available online throughout the meeting. Be sure to download the CNSF Congress app to your phone to access all electronic media and program content.

I would like to thank all CNSF Societies, and the CNSF Executive and Board, for their engagement and accountability in moving the CNSF forward. The federation exists as a function of all six societies, and our objective is to see all our member societies flourish. The Canadian Journal of Neurological Sciences (CJNS) has a new Editor-in-Chief, Dr. Tejas Sankar, who is based at the University of Alberta and is the first neurosurgeon to serve in this role. We thank Robert Chen for his stewardship of the journal over many years; the journal continues to have both a rising impact factor and to make a small surplus. With engagement from new member societies in the CNSF it will continue to prosper. The future of the CJNS looks bright.

We are continuing to focus on the mission of expanding the role of the CNSF to represent clinical neurosciences in Canada.

We have expanded membership to include the Canadian Association of Neuroscience Nurses and the neurophysiology technicians. We are working towards agreements for allied members with the Canadian Association of Neuropathology and the Canadian Pain Society. This process will take a couple of years to evolve and solidify, but I am hopeful that we can embrace all health care practitioners in neuroscience and make the federation a place for them to thrive. We further encourage each of you to bring your existing colleagues into one of the societies and become part of the organization. We will increasingly make the CNSF, the voice of clinical neuroscience in critical areas for advocacy such as health workforce planning, remuneration, insurance, patient access to new drugs, technologies, and procedures and more.

Finally, thanks to the CNSF Secretariat, led by Dan Morin, who have shown tremendous adaptability and ongoing success of the CNSF.

Michael D Hill, MD FRCPC
President, CNSF

CSNF Online

Visit the CNSF Website: cnsf.org

- Quick access to Webinars, Neuro Career listings, CJNS Journal, Congress info and the latest news
- Keep up with society initiatives and highlights by visiting your Society page
- Visit the new Advocacy Hub and Neuro Surveys pages for Members

We value our members’ input and support – thank you!

Follow us on Twitter: twitter.com/CNSFNeuroLinks
Like us on Facebook: facebook.com/CNSFNeuroLinks
Follow us on Instagram: instagram.com/cnsfneurolinks
Follow us on LinkedIn: linkedin.com/company/canadian-neurological-sciences-federation
CNSF Mission
To support the neuroscience professions in Canada, and particularly those members of the CNSF Societies, through education, advocacy, membership services and research promotion.

Notes about the Mission:

• **Education** includes the annual CNSF Congress, The Canadian Journal of Neurological Sciences (CJNS), and all other continuing professional development (CPD) activities.

• **Membership Services** include services delivered to the constituent Societies of the CNSF and their individual members, the research to identify member needs, and other related activities.

• **Advocacy** includes activities such as building public awareness about diseases, disorders and injuries of the nervous system, and advocacy for improved public policy and increased medical research. Such advocacy may be direct or in collaboration with other organizations.

CNSF Values
An organization’s values convey those non-negotiable elements in how the mission is implemented in pursuit of the vision. Values mean that outcomes are not the only thing that matters — how outcomes are achieved is also important. Success is not only determined through outcomes, but also through conduct and approach.

**Excellence in Education:** Continuing professional development is a cornerstone of the success of the individual practitioner, the profession, and the member societies. Accordingly, all CNSF educational efforts must reflect excellence in their quality, relevance and delivery.

**Representative and Inclusive:** The CNSF is a Federation of Societies representing diverse and collegial medical professionals with a common focus on diseases, disorders, and injuries of the nervous system. Accordingly, the CNSF must reflect and engage these Societies and their members in how it works and what it does.

Strategic Priorities
To ensure the achievement of its Vision and Mission, the CNSF has three strategic priorities: Continuing Professional Development, Membership Value, and Advocacy. The goals of these three priorities are noted below. Responsibility for expanding and putting these elements into operation has been assigned to one or more of the CNSF constituent societies, committees, or staff.

1. **Continuing Professional Development:** The goal of this priority is to review, refine, improve and expand the overall CNSF CPD plan to meet the evolving needs of Society members while continuing to focus on the CNSF’s priorities, i.e. the Congress and the CJNS Journal.

2. **Membership Value:** The goal is to build a strong organization that provides value to the constituent Societies and their membership.

3. **Advocacy:** The goal is to increase awareness of the impact and burden of diseases, disorders and injuries of the nervous system in Canada on affected individuals, their families, and communities, and the health-care system. The targets of this priority are the policymakers at all levels of government, the general public and affiliated health care providers.

A Strong and Effective Voice: The well-being of individuals with diseases, disorders, and injuries of the nervous system and, where possible, the prevention of these conditions, comprise an important vision. The work of the member societies and their respective members is also important. The CNSF must advocate with a strong and effective voice knowing that its mission and vision have unique and important value to society.

Responsible Stewardship: The CNSF’s financial resources are secured from the dues paid by the professionals of its constituent Societies and from commercial sponsors who support its vision and mission. The CNSF has an obligation to the professionals of its constituent Societies to manage these resources wisely, maintain good governance practices, and conform to the standards established by the responsible agencies (e.g. governments, the RCP&SC, provincial and territorial regulatory bodies).

cnsf.org/about-cnsf
ULTOMIRIS® (ravulizumab for injection) is indicated for the treatment of adult patients with anti-acetylcholine receptor (AChR) antibody-positive generalized Myasthenia Gravis (gMG).

ULTOMIRIS® was studied in adult gMG patients with a Myasthenia Gravis Foundation of America (MGFA) clinical classification Class II to IV and a Myasthenia Gravis Activities of Daily Living (MG-ADL) total score ≥6.

Consult the product monograph at https://alexion.com/documents/ultomiris_product_monograph_approved_english for important information relating to:

- Contraindication in patients with unresolved Neisseria meningitidis infection.
- The most serious warning and precaution regarding serious meningococcal infections.
- Conditions of clinical use, adverse reactions, drug interactions, and dosing instructions.

The product monograph is also available by calling 1-844-922-0605.

References:
CNSF at a Glance

- The CNSF’s major priorities, as determined by the CNSF Board’s Strategic Planning document are: Continuing Professional Development (through the Congress and the CJNS journal); Advocacy and Membership retention and growth.

- The CNSF has four main sources of revenue: Membership dues, Congress registration fees, Journal subscription revenue and Industry sponsorship. All four are vital to our continued success and growth.

- It is very important that our Members renew their membership each year and we hope that each member can recruit others to join. The benefits of membership page is included in this Neuro|News and a Power Point presentation on “The CNSF and why you should join” is on our website. cnsf.org

- The Federation has six Member Societies and continues to take steps to grow its Neuroscience portfolio.

- The CNSF has five staff: Donna, Nicole, Kasandra, Dara, and Dan.

- We ‘contract’ services to third parties such as Intertask Conferences for the Congress and Cambridge University Press for the CJNS Journal.

cnsf.org/about-cnsf-membership/benefits-of-cnsf-membership
www.cnsf.org

2025 CNSF Congress in Ottawa
Monday, June 9 – Thursday, June 12

Join your colleagues at the Fairmont Château Laurier Hotel and Shaw Centre Hope to see you there!
CNSF Board of Directors 2023–2024

Michael D Hill
CNSF President
CNS, CSC Member

Kesh Reddy
CNSF Past President
CNSS Member

Pat McDonald
CNSF Vice-President
CNSS Member

Cecil Hahn
CNSF Vice-President
CACN, C SCN Member

Fraser Moore
CNSF Vice-President
CNS, C SCN Member

Donatella Tampieri
CNSF Vice-President
CSNR Member

Christian Stapf
CNSF Vice-President
CSC Member

Steven Peters
CNS President

Alice Schabas
CNS Vice-President

John Wong
CNSS President

Gwynedd Pickett
CNSS Vice-President

Steven Baker
CSCN President

Marcus Ng
C SCN Vice-President

Michael Esser
CACN President

Sunita Venkateswaran
CACN Vice-President

Rob Sevick
CSNR President

Matthias Schmidt
CSNR Vice-President

Andrew Demchuk
CSC Chair
CNSF Board of Directors 2023–2024

Ashfaq Shuaib
CSC Vice-Chair

Aleksandra Mineyko
CNSF At-Large

Ian Fleetwood
CNSF At-Large

Cian O’Kelly
CNSF PDC Chair
CNSS Member

Joseph Megyesi
CNSF SPC Chair
CNSS Member

Tejas Sankar
CJNS
Editor-In-Chief
CNSS Member

Jeanne Teitelbaum
CNSF Membership Committee Chair
CNS, CSC Member

Draga Jichici
CNSF CPGC Chair
CNS Member

Dan Morin
CNSF
Chief Executive officer

Michael D Hill
CNSF Advocacy Committee Chair
CNS, CSC Member

Emma Woo
CNS
Sr. Resident Rep

Cathy Meng Fei Li
CNS
Sr. Resident Rep

Darek Sokol-Randell
CNS
Jr. Resident Rep

Katherine Tourigny
CNSS
Sr. Resident Rep

Sam Molot-Tokor
CNSS
Jr. Resident Rep

Jessie Kulaga-Yoskovitz
CACN
Sr. Resident Rep

Dakota Peacock
CACN
Jr. Resident Rep

Jacky Chow
CSNR
Resident Rep
2023–2024 Society Boards of Directors and Committee Reps

The Canadian Neurological Sciences Federation (CNSF) is comprised of member Societies, representing different specialties of the Neurosciences. Each society has a volunteer Board of Directors.

Special thanks to these dedicated volunteers that served in 2023-2024. Their input of time and experience contributes to the success of their individual Society as well as collectively to CNSF initiatives.

Board member rosters will be updated after each society’s AGM in May.

Canadian Neurological Society (CNS)

CNS President ..............................................Steven Peters
CNS Vice President ......................................Alice Schabas
CNS Secretary Treasurer ...............................Pardh Chivukula
CNS Past President .......................................Steven Peters
Director from British Columbia .......................Alex Henri-Bhargava
Director from Alberta ....................................Brian Buck
Director from Saskatchewan .........................Ili Poliakov
Director from Ontario ....................................Andrew Kirk
Director from Manitoba .................................James Marriott
CNSF Executive Committee
CNSF Board of Directors
CNSF Advocacy Committee
CNSF Clinical Practice Guidelines Committee
CNSF SPC Committee
CNSF Membership Committee
CNSF PDC Committee
CNSF Representative(s) on:
Canadian Neurosurgical Society (CNSS)

CNSS President ..............................................John Wong
CNSS Vice President ......................................Gwynedd Pickett
CNSS Secretary Treasurer ...............................David Steven
CNSS Past President .......................................Dhany Charest
Director from British Columbia .......................Ian Fleetwood
Director from Alberta .....................................Vivek Mehta
Director from Saskatchewan ...........................Luke Hnenny
Director from Manitoba ..................................Colin Kazina
Director from New Brunswick.........................Aron Robichaum
Director from Nova Scotia ..............................Sean Christie
Director from Newfoundland & Labrador ............Roger Avery
Director and CNSF CEO .................................Dan Morin
Residents Representatives .............................Emma Woo, Cathy Meng Fei Li
Canadian Neurosurgical Society (CNSS)

CNSF Representative(s) on:

CCNSS Choosing Wisely Campaign...............Gwynedd Pickett
CNSF PDC Committee .................................Cian O’Kelly (Chair), and Resident Reps
CNSF SPC Committee .................................Joseph Megyesi (Chair), and Resident Reps
CNSF Membership Committee ......................Ian Fleetwood, and Resident Reps
CNSF Clinical Practice Guidelines Committee ....Joseph Megyesi, Tejas Sankar
CNSF Advocacy Committee .........................Michael Tso, Pat MacDonald
CNSF Board of Directors .........................John Wong, Gwynedd Pickett
CNSF Executive Committee ...........................Tejas Sankar (CNSF VP) 2023 / Pat McDonald (CNSF VP) 2024

CNS Representative(s) on:

CNSF Choosing Wisely Campaign ..................Philippe Couillard
WFN Representative .................................Andrew Kirk
CNSF PDC Committee .................................Gerald Pfeffer, Draga Jichici, Bastien Rioux
CNSF SPC Committee .................................Jeanne Teitelbaum (Chair), Michael D Hill and Resident Reps
CNSF Membership Committee ...............Jeanne Teitelbaum (Chair), Michael D Hill and Resident Reps
CNSF Clinical Practice Guidelines Committee ....Draga Jichici (Chair), Jeanne Teitelbaum
CNSF Advocacy Committee ...............Michael D Hill (Chair), Linda Magnusson
CNSF Board of Directors ......................Steven Peters (CNSF VP)
CNSF Executive Committee ..................Michael D Hill (CNSF President)
Canadian Society of Clinical Neurophysiologists (C SCN)

C SCN President ................................................................. Steve Baker
C SCN Vice President .......................................................... Marcus Ng
C SCN Secretary Treasurer ................................................... Christine Stables
C SCN Past President ......................................................... Juan Pablo Appendino
EEG Section Chair .............................................................. Michelle-Lee Jones
EEG Section Secretary .......................................................... Robyn Whitney
EEG Chief Examiner ............................................................ Cecil Hahn
EMG Section Chair ............................................................ Cecile Phan
EMG Section Secretary ....................................................... Dina Namiranian
EMG Chief Examiner ........................................................... Steve McNeil
Director and CNSF CEO ..................................................... Dan Morin

C SCN Representative(s) on:
- CNSF PDC Committee ....... Seyed Mirsattari
- CNSF SPC Committee ........ Michelle Mezei (Vice Chair), Kristen Ikeda
- CNSF Clinical Practice Guidelines Committee ... JP Appendino, Steve Baker
- CNSF Advocacy Committee ........ Steve Baker, Fraser Moore
- CNSF Board of Directors ........ Steve Baker, Marcus Ng
- CNSF Executive Committee ........ Fraser Moore (CNSF VP)

Canadian Association of Child Neurology (CACN)

CACN President ................................................................. Michael Esser
CACN Vice President .......................................................... Sunita Venkateswaran
CACN Secretary Treasurer ................................................... Anita Datta
CACN Past President ........................................................... Colin Wilbur
Director from Western Canada .................. Aoife O’Carroll / Samantha Marin
Director from Eastern Canada .................. David Dufresne
Director and CNSF CEO ..................................................... Dan Morin
Residents Representatives ... Jessie Kulaga-Yoskovitz, Dakota Peacock (Jr)

CACN Representative(s) on:
- CACN Education Committee ........ David Callen (Chair), Sunita Venkateswaran, Alex Mineyko
- CACN Community Practice Pediatric Neurologist ........... Dragos Nita, Wendy Stewart
- CPSP ................................................................. Elizabeth Donner
- CNSF PDC Committee ........ Maryam Nouri, and Resident Reps
- CNSF SPC Committee ... Hugh McMillan, David Callen, and Resident Reps
- CNSF Membership Committee ........ David Callen, and Resident Reps
- CNSF Clinical Practice Guidelines Committee ........... Thilinie Rajakapakse
- CNSF Advocacy Committee ........ Elizabeth Donner, Michael Esser / Natarie Liu, Stephanie DeGasperis
- CNSF Board of Directors ........ Michael Esser, Sunita Venkateswaran
- CNSF Executive Committee ............... Cecil Hahn (CNSF VP)

Canadian Society of Neuroradiology (CSNR)

CSNR President ................................................................. Rob Sevick
CSNR Vice President .......................................................... Matthias Schmidt
CSNR Secretary Treasurer .................................................. Laila Alshafai
CSNR Past President ......................................................... Donatella Tampieri
Director from Manitoba ...................................................... Jai Shankar
Director from Manitoba ...................................................... Nima Kashani
Director from Ontario ....................................................... Timo Kronis
Director from Ontario ....................................................... William Miller
Director and CNSF CEO ..................................................... Dan Morin
Residents Representative ................................................... Jacky Chow

CSNR Representative(s) on:
- CSNR Social Media ...................................................... Carmen Parra-Fariñas
- CSNR Webinar Series ...................................................... Jai Shankar, Carmen Parra-Fariñas
- CSNR CING ............................................................... Donatella Tampieri, Jai Shankar
- CSNR ASNR ................................................................. Timo Kronis
- CSNR Canadian Neuroradiology Course CNRC ............. Timo Kronis
- CSNR CAR ................................................................. William Miller
- CNSF PDC Committee ........ Jai Shankar and Resident Rep
- CNSF SPC Committee ........ Jai Shankar, Laila Alshafai, Manohar Shroff and Resident Rep
- CNSF Membership Committee ........ Carmen Parra-Fariñas, and Resident Rep
- CNSF Clinical Practice Guidelines Committee ........ Donatella Tampieri, Kathleen Jacobs
- CNSF Advocacy Committee ........ William Miller, Jai Shankar
- CNSF Board of Directors ........... Rob Sevick, Matthias Schmidt
- CNSF Executive Committee ............... Donatella Tampieri (CNSF VP)

Canadian Stroke Consortium (CSC)

Chair ................................................................. Andrew Demchuk
Deputy Chair ............................................................... Leanne Casaubon
Deputy Chair ............................................................... Dar Dowlatabadi
Finance Chair .............................................................. Alex Thiel
Past Chair ................................................................. Mike Sharma
Board Member ............................................................. Alex Thiel
Board Member ......................................................... Ashkan Shoamansheh
Board Member ......................................................... Dar Dowlatabadi
Board Member ......................................................... Dylan Blacquiere
Board Member ..........................................................
Michael Hill
Board Member ..........................................................
Sashi Perera
Board Member ..........................................................
Jennifer Mandzia
Board Member ......................................................... Leanne Casaubon
Board Member ......................................................... Michael Hill
Board Member ..........................................................
Sashi Perera
Board Member ..........................................................
Leanne Casaubon
Board Member ..........................................................
Sahi Perera
Board Member ..........................................................
Ashfaq Shuaib (CSC Member)
Board Member .............................................................
Christian Stapf (CNSF VP)

CSC Representative(s) on:
- CCNSF SPC Committee ........ Christine Hawkes, Mahesh Kate, Ravinder Singh
- CNSF Clinical Practice Guidelines ........... Christian Stapf
- CNSF Advocacy Committee ........ Regan Cooley, Dylan Blacquiere
- CNSF Board Member ............... Ashfaq Shuaib (CSC Member)
- CNSF Executive Committee ............... Christian Stapf (CNSF VP)
Benefits of CNSF Membership

Our Member Societies

CNSF members belong to one, or more, of our Societies:

- **Canadian Neurological Society (CNS)** cnsf.org/cns/about-cns
  *Annual General Meeting:* Wednesday, May 22 at 4:15 pm

- **Canadian Society of Clinical Neurophysiologists (CSCN)** cnsf.org/cscn/about-cscn
  *Annual General Meeting:* Thursday, May 23 at 7:00 am

- **Canadian Neurosurgical Society (CNSS)** cnsf.org/cnss/about-cnss
  *Annual General Meeting:* Thursday, May 23 at 4:30 pm

- **Canadian Association of Child Neurology (CACN)** cnsf.org/cacn/about-cacn
  *Annual General Meeting:* Thursday, May 23 at 4:30 pm

- **Canadian Society of Neuroradiology (CSNR)** cnsf.org/csnr/about-csnr
  *Annual General Meeting:* Thursday, May 23 at 4:30 pm

- **Canadian Stroke Consortium (CSC)** cnsf.org/csc/about-csc

Membership in the Community of Canadian Clinical Neuroscientists

The community of clinical neurologists, neurosurgeons, pediatric neurologists, neurophysiologists and neuroradiologists is a robust and growing family that has made a long-standing, international, and ongoing contribution to clinical neuroscience. The community provides continuing medical education for its members, teaching for residents, students and clinical fellows. There is strong clinical and discovery-based research in Canada. Networking in this group provides for collaboration across the country, for mutual learning and the opportunity for training (e.g. fellowships).

Congress

Our Federation, assisted by the Professional Development and the Scientific Program Committees, hosts a Canadian Congress geared towards the Continuing Professional Development (CPD) learning needs of Neurologists, Neurosurgeons, Pediatric Neurologists, Neurophysiologists, Neuroradiologists and Neuroscientists.

Our Congress is an accredited learning activity; therefore, you earn Maintenance of Certification (MOC) credits.

Gather with your colleagues and friends from across the country. Learn, Mentor, Share, Teach, Collaborate, Advocate.

Members attend the CNSF Congress at a generously discounted registration fee.

Society Prize Awards

Members have the opportunity to win valuable society prizes by submitting an 'Abstract' to the Congress as well as an 'Expanded Abstract' to the society competitions.

There are multiple first place prizes available to Junior Members or a Full Member within two years of receiving their Royal College certificate. Each valued at approximately $2500.

Winners will be given a designated time to present their work at the CNSF Congress. Prize winners will be announced in the Neuro|News newsletter, in the Canadian Journal of Neurological Sciences and on the CNSF website.

$500 second place prizes and additional subsidiary prizes may be awarded.

Canadian Journal of Neurological Sciences

The Canadian Journal of Neurological Sciences (CJNS) is the official publication of our member Societies. The CJNS journal is an internationally recognized, peer reviewed medical journal, published through Cambridge University Press – Cambridge Core.

Members receive an online subscription with exclusive access to the most current year of publication. CNSF Members submitting an article to the CJNS receive GOLD open access at half price.
Not a member of the CNSF?

Would you like to become a member of one of the CNSF National Specialty Societies?

Would you like to take advantage of the Benefits of CNSF Membership?

Download the appropriate society application form by choosing your society of interest or contact Donna Irvin, CNSF Member Services at: donna-irvin@cnsf.org / www.cnsf.org

Become a Member | CNSF
cnsf.org/about-cnsf/membership/become-a-member

The CNSF – Why You Should Join

Member Only Information

Members receive CNSF Neuro | News bi-monthly electronic newsletter featuring:

- Society and Federation news
- Congress details and updates
- Job postings
- Advocacy items
- Messages from the CNSF and Society Presidents
- CJNS Journal Highlights
- Webinars and other CNSF CME Opportunities
- Continuing Professional Development (CPD) opportunities

Access to additional information on the CNSF website.

Our website contains the latest information for our National Specialty Societies and all that the Canadian Neurological Sciences Federation has to offer. Members receive the added benefit of ‘member only’ information such as CJNS journal access, past webinar recordings, quick access to Society driven initiatives, information, and resource links.

Society Initiatives

Members receive all benefits outlined in the sections above as well as any additional benefits provided by their individual Society, such as:

- CNSS and CACN Lifetime Achievement Awards
- CSCN EMG and EEG Certification exams
- CACN Grand Rounds
- CSC and CSNR Webinars and past recordings

Residents

PGY1 residents can apply for complimentary first-year membership, paid by their member Society. Membership dues for subsequent years of residency are only $80/year.

Congress registration fees for resident members is only $250. This registration fee includes access to all Congress courses/sessions, course notes, luncheons, breaks and the Residents Social.

CNSF Society Resident Representatives help organize a resident social event at the Congress. This is a major networking event for trainees to connect with attending physicians from a wide variety of backgrounds and subspecialties.

The newest benefit for our Junior members is the CNSF prepOSCE neurology sessions, offering virtual practice OSCE sessions for PGYS members preparing for their Royal College exams.

Resident members receive all benefits outlined in the sections above as well as any additional benefits provided by their individual Society, such as CNS and CACN Canadian Leaders in Neurology interviews for publication in the CJNS and the CNS and CACN Mentorship Programs. Resident representatives from both the CNS and CACN have also created listings for Canadian fellowship opportunities.

The CNS, CNSS, CACN and CSNR all have resident representatives that sit on the CNSF Professional Development and Scientific Program Committees and attend the CNSF Board of Directors meetings, as well as their respective Society Board meetings.

Resident members are welcome to contact their society resident representative with any issues, concerns, or ideas that they would like to see discussed.
ZOLGENSMA®: The first one-time-only gene therapy indicated in the treatment of pediatric patients with 5q spinal muscular atrophy (SMA)\(^1,2\)*

1X ZOLGENSMA® IS ADMINISTERED AS A SINGLE-DOSE INTRAVENOUS INFUSION\(^1\)

3,500+ PATIENTS HAVE BEEN TREATED WITH ZOLGENSMA® GLOBALLY\(^3\)

Please see the Product Monograph for complete dosing and administration information.

ZOLGENSMA® (onasemnogene abeparvovec) is indicated for the treatment of pediatric patients with 5q spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene and:

- 3 or fewer copies of SMN2 gene; or
- infantile-onset SMA

Consult the Product Monograph at www.novartis.ca/ZolgensmaMonograph for information regarding warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by contacting 1-800-363-8883 or medinfo.canada@novartis.com.

* Comparative clinical significance is unknown.

Resident Interviews with Canadian Leaders in Neurology | Pediatric Neurology

The Canadian Journal of Neurological Sciences (CJNS) publishes a series of resident interviews with Canadian Leaders in Neurology. These interviews focus on mentorship, career pearls, and the future directions of Canadian neurology. This is an initiative of the Canadian Neurological Society and the CNS Resident Representatives. The resulting interviews have proven to be intelligent, insightful, and fun. They also provide rewarding experiences and connections for both the resident and their featured “leader”.

In 2023, the series expanded to include Canadian Leaders in Pediatric Neurology, accepting interview submissions from CACN resident members, and we are pleased to feature our first published interview of a Canadian Leader in Pediatric Neurology.

View all previous interviews: cnsf.org/cns/about-cns/canadian-leaders-in-neurology

Most recent interview and the first published interview of a Canadian Leader in Pediatric Neurology

cnsf.org/cacn/about-cacn/canadian-leaders-in-pediatric-neurology

Featured: Dr. Steven Miller
Interviewed by Dr. Dakota Peacock
https://doi.org/10.1017/cjn.2024.15

If you are a Junior member of the CNS or the CACN, and you are interested in interviewing a leader in your specialty, please contact: donna-irvin@cnsf.org

MEET YOUR MENTOR!

Canadian Association of Child Neurology (CACN) Mentorship Program

The Canadian Association of Child Neurology (CACN) Mentorship Program began in 2017 and has successfully connected dozens of pediatric neurology residents with staff pediatric neurologists across the country. Mentorship is a rewarding and beneficial experience.

Pediatric neurology is a diverse specialty. CACN mentor/mentee matches are made based on specific interests and career track within Pediatric Neurology, regardless of Canadian geographic locations.

The annual CNSF Congress is a great opportunity to meet your mentor in person!

If you are interested in participating in this program, as either a Mentor or a Mentee, you will find details on the CACN residents webpage: cnsf.org/cacn/about-cacn/residents-page

Canadian Neurological Society (CNS) Mentorship Program

The Canadian Neurological Society (CNS) began a similar mentorship program in 2022.

This was created to bolster the professional development of trainees of all levels and early career neurologists by connecting them with experienced neurologists with similar career goals and interests.

The CNS Mentorship Subcommittee has designed a framework for matching mentors and mentees that takes into consideration the diverse landscape and evolving needs of neurology trainees and neurologists across Canada.

The annual CNSF Congress is a great opportunity to meet your mentor in person!

Skillful mentorship is an immensely fulfilling experience and it has enduring beneficial effects for both the mentee and mentor. If you are interested in becoming a mentee or a mentor, you will find all details on the CNS residents webpage: cnsf.org/cns/about-cns/residents-page

The annual CNSF Congress is a great opportunity to meet your mentor in person!
OCREVUS indicated for: the management of adult patients with early primary progressive multiple sclerosis (PPMS) as defined by disease duration and level of disability, in conjunction with imaging features characteristic of inflammatory activity has been issued market authorization with conditions, pending the results of trials to verify its clinical benefit. Patients should be advised of the nature of the authorization. For further information for OCREVUS, please refer to Health Canada’s Notice of Compliance with conditions - drug products web site: https://www.canada.ca/en/health-canada/services/drugshealth-products/drug-products/notice-compliance/conditions.html

OCREVUS, indicated for: the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical and imaging features has been issued market authorization without conditions.

Only ONE therapy is indicated in the treatment for PPMS & RRMS.

OCREVUS: Dosed every 6 months following the initial dose

**INITIAL DOSE**

Day 1

- 300 mg

**SUBSEQUENT DOSES**

Every 6 months

- 600 mg

Doses of OCREVUS must be separated by at least 5 months

**IF patients did not experience a serious infusion-related reaction with any previous OCREVUS infusion, a shorter (2-hour) infusion can be administered for subsequent doses.**

**Option 1: 2 hours**

(if no serious infusion reactions with any previous OCREVUS infusion)

**Option 2: 3.5 - 4 hours**

Patients should be observed for at least one hour after the completion of the infusion.

Please consult the Product Monograph at http://www.rochecanada.com/PMs/Ocrevus/OCREVUS_PM_E.pdf for important information relating to contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use.

The Product Monograph is also available by calling us at 1-888-762-4388.

*As of July 2023. Clinical significance has not been established.

§ Comparative clinical significance unknown.


If you require this information in an accessible format, please contact Roche at 1-800-561-1759.
Dr. Joseph Megyesi received the 2024 Canadian Neurological Sciences Federation’s Distinguished Service Award. This award is given to a senior member of the CNSF who has made an outstanding, notable, or special contribution to the Canadian Neurological Sciences Federation, and to one or more of the Federation’s Societies and/or the CJNS (Journal); either through participation in the CNSF’s committees, involvement in the Congress, the performance of administrative duties, or involvement in promoting the CNSF and its member societies.

Dr. Megyesi joined the Canadian Neurological Sciences Federation (CNSF) as a member of the Canadian Neurosurgical Society (CNSS) after becoming a staff neurosurgeon in the Department of Clinical Neurological Sciences (CNS) at LHSC-University Hospital and Western University in London, Ontario. Prior to this he completed medical school at Western University and neurosurgical residency at the University of Alberta in Edmonton. He obtained a Masters degree in biochemistry from Western University and a PhD in experimental surgery from the University of Alberta. He attended Harvard University as a Medical Research Council (MRC) of Canada Fellow where he worked with Dr. Judah Folkman at Boston Children’s Hospital. He joined the CNS Department at the LHSC and Western University in 1998, where he is now professor in the Division of Neurosurgery.

Dr. Megyesi’s involvement with the CNSF and CNSS has included being chairman and vice-chairman of the Professional Development Committee (PDC) and chairman and vice-chairman of the Scientific Program Committee (SPC). The advent of the covid pandemic allowed/required Dr. Megyesi to be the SPC chair for an extended period of time, covering the Montreal Congress in 2022, the Banff Congress in 2023 and the Toronto Congress in 2024. In this role he helped with the planning of this year’s 100 Years of Neurosurgery in Canada celebration at the University of Toronto. Dr. Megyesi has represented the CNSF at the annual National Accreditation Conference (NAC) and has been the National Speciality Society (NSS) representative for the CNSF on the Royal College of Physician and Surgeons of Canada (RCPSC) Continuing Professional Development (CPD) Accreditation.
WHEN THEIR FOCAL SEIZURE JOURNEY LEADS TO AN ADJUNCTIVE TREATMENT, CHOOSE XCOPRI

XCOPRI is indicated as adjunctive therapy in the management of partial-onset seizures† in adults with epilepsy who are not satisfactorily controlled with conventional therapy.1

Consult the Product Monograph at https://www.endodocuments.com/XCOPRI/MONOGRAPH/CAN/ENG for important information on contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling us at 1-888-867-7426.

* Clinical significance has not been established.
† Partial-onset seizures are now referred to as focal seizures per the International League Against Epilepsy.1

ASM=anti-seizure medication.


XCOPRI® is a registered trademark of SK Biopharmaceuticals Co., Ltd.
© 2024 Paladin Labs Inc., St-Laurent, QC
March/2024
Dr. Joseph Megyesi, continued

Committee. His involvement with the Royal College continues as he now serves on other related committees. Dr. Megyesi is also a member of the CNSF guidelines committee and is a member of the editorial board of the Canadian Journal of Neurological Sciences (CJNS), where he was Distinguished Reviewer of the Year in 2010. Dr. Megyesi has chaired the McKenzie Prize adjudication committee at the CNSS for several years. Dr. Megyesi has been a chair/co-chair/speaker at many of the CNSF Congresses and has particularly enjoyed his involvement with the organization of the Neurosurgery Resident Review Courses.

During his day job at the London Health Sciences Centre (LHSC) and Western University, Dr. Megyesi supplements his clinical duties with both education and research endeavours. He is a member the CNS Department Education Committee and the CNS Department Research Committee. He organizes the neurosurgery resident seminar teaching and has organized the neurosurgery journal club as well as CNS departmental CPD events. Until recently he organized the CNS Department Research Day along with neurology colleague Dr. David Macdonald. He has been principal supervisor/co-supervisor/mentor to undergraduate students, graduate students, residents, and fellows. He has published scientific papers and served as peer reviewer for a number of scientific journals and various granting agencies. He is on the organizing committee of the annual national Ottawa Neurosurgery Review Course.

He is the regional representative in neuro-oncology for Cancer Care Ontario. With neuropathology colleague Dr. Robert Hammond and neuro-radiology colleague Dr. Andy Leung he developed the free on-line case-based learning tool called medCBL (medcbl.com) for neuroscience residents, fellows and consultants. Recently he was awarded the Angelika F. Hahn Award for Excellence in Clinical Teaching at Western University and was the invited Michael T. Richard Visiting Professor in Neurosurgery at the University of Ottawa.

Dr. Megyesi has been a volunteer with Brain Tumour Foundation of Canada (BTFC) for over 30 years, extending back to medical school. He served as the Chairman of the Board of Directors for six years. He has been chair of the research committee and served on several other committees, including advocacy, support and finance. His work led to the reinstitution of a research grant competition, a research fellowship competition, and an undergraduate/medical student research competition at the BTFC. He is co-director of the BTFC Brain Tumour Tissue Bank located at the LHSC-University Hospital in London, Ontario. He helped the BTFC to become a founding member of the North American Brain Tumor Funders Collaborative and laid much of the groundwork for the BTFC to partner with academia to create the Canadian Brain Tumour Registry, now the leading source of data to monitor brain tumour incidence rates in Canada. For his work with the BTFC he received an Ontario Volunteer Service Award in 2017.

Dr. Megyesi enjoys travel and photography. Trips include hikes to the summit of Mount Kilimanjaro in Tanzania, to Everest Base Camp in Nepal, to the summit of Half Dome in Yosemite National Park, USA, to the summit of Mount Fuji in Japan, a circuit hike around Mount Blanc in Europe, and a hike along the entire West Coast Trail in British Columbia, Canada.

He has created a yearly calendar which includes photographs from many of these trips. This calendar is produced for the Brain Tumour Foundation of Canada and is distributed to donors as well as neuroscience colleagues. Dr. Megyesi wishes to thank all the neuroscience colleagues that he has worked with over the years, especially those in neurosurgery, as well as Dan Morin and the staff at the CNSF.

Joe, on the behalf of the CNSF Executive and Board, CNSF Members, and the Secretariat, thank you for your dedication to the CNSF in the past, the present and hopefully for years to come.
Our Commitment to Transthyretin Amyloidosis

At AstraZeneca, we believe in the power of what science can do in transforming the care of life-threatening diseases.

AstraZeneca is proud to support the 2024 Canadian Neurological Sciences Federation’s Congress as part of our commitment to advancing next generation therapeutics for people living with Transthyretin Amyloidosis
Dr. Rutka is an internationally celebrated translational neuro-oncologist with appointments at SickKids and the University of Toronto (UoFT). He is a Neurosurgeon and Senior Scientist in the Cell Biology Program at SickKids. He is also a Professor in the Faculty of Medicine and holds the RS McLaughlin Chair within the Department of Surgery at the University of Toronto.

Dr. Rutka was born in Toronto, educated at Princeton University and Queen's University Medical School, and completed an internship at McGill University prior to entering UoFT's Neurosurgery Training Program in 1982. He pursued further training at the University of California, San Francisco and Juntendo University, Tokyo. In 1990, he joined SickKids and secured a position with the surgical staff in the Division of Paediatric Neurosurgery. In the three decades since he joined SickKids, Dr. Rutka’s research laboratory has made incredible breakthroughs on devastating brain tumours that affect children, called astrocytomas and medulloblastomas. Dr. Rutka has also cultivated significant expertise and is widely published on the surgical treatment of epilepsy in children.

His work has attracted international attention, earned him numerous distinctions and accolades, and positioned Canada as a front-runner in the study of brain tumours and epilepsy surgery. He is admired for his thirty years of leadership in neuro-oncology and epilepsy, his research discoveries, and his ongoing ground-breaking science.

Dr. Rutka has mentored an extensive number of trainees from around the world over his career. He has supervised 22 graduate students, 28 post-doctoral fellows, and 5 post-graduate MDs. Many of his trainees have gone onto establish world renowned laboratories, including Drs. Michael Taylor and Peter Dirks who have revolutionized the field of paediatric oncology in their own fields.

Dr. Rutka is an exemplary surgeon and scientist of extraordinary intellect, who is dedicated to excellence in research and in paediatric care. He is recognized around the world for his field-changing work in neuro-oncology and the implementation of basic research within the clinical areas of paediatric oncology and paediatric neurosurgery. He is an invaluable contributor of innovative and ground-breaking science, and has an unwavering commitment to addressing the most challenging conditions affecting paediatric patients. His leadership and visionary approach to research work, his contributions to Canada and beyond, as well as his obvious investigative and clinical excellence make Dr. Rutka the most ideal and deserving recipient of this distinction.
A CHOICE FOR YOUR PATIENT’S FIGHT AGAINST ALS

RADICAVA® Oral Suspension and RADICAVA® IV are indicated for the treatment of patients with amyotrophic lateral sclerosis (ALS).

In a 24-week, randomized, placebo-controlled, double-blind study in 137 Japanese patients with ALS:

RADICAVA® IV Infusion slowed the loss of functional ability at 24 weeks (as measured by the ALSFRS-R scores).

less change from baseline compared to placebo (LS mean change in ALSFRS-R scores from baseline vs placebo: -5.01 vs -7.50; 2.49 point difference [95% CI: 0.99–3.98], p=0.0013)*†

The efficacy of RADICAVA® Oral Suspension is based on the comparative bioavailability study of RADICAVA® IV and RADICAVA® Oral Suspension in healthy subjects, demonstrating comparable exposure with both formulations.

Clinical use:
- Pediatrics (<18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use.
- Geriatrics (≥65 years of age): Use in the geriatric population is not associated with differences in safety or effectiveness.

Contraindications:
RADICAVA® Oral Suspension is contraindicated in patients who are hypersensitive to the drug or any ingredient in the formulation.

Relevant warnings and precautions:
- Neurologic events
- Hypersensitivity reactions
- Sulfite allergic reactions
- Skin-related events
- Use in pregnant and breastfeeding women

For more information:
Please consult the Product Monograph at RADICAVA.ca/pm for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use.

The Product Monograph is also available through our medical department at 1-888-212-2253.

RADICAVA, the RADICAVA Oral Suspension logo, and the corporate symbol of Mitsubishi Tanabe Pharma Canada are trademarks of Mitsubishi Tanabe Pharma Corporation, used under license by Mitsubishi Tanabe Pharma Canada, Inc. MTP Patient Support is a trademark of Mitsubishi Tanabe Pharma Canada, Inc. © 2024 Mitsubishi Tanabe Pharma Canada, Inc. All rights reserved. CP-OE-CA-0030 03/24

ALSFRS-R: ALS Functional Rating Scale – Revised.
*Results from a 6-month, randomized, placebo-controlled, double-blind study in which 137 patients with ALS were randomized to receive RADICAVA® IV (n=69) and placebo (n=68). RADICAVA® IV was administered as an intravenous infusion of 60 mg given over a 60-minute period according to the following schedule: An initial treatment cycle with daily dosing for 14 days, followed by a 14-day drug-free period (Cycle 1); subsequent treatment cycles with daily dosing for 10 days out of 14-day periods, followed by 14-day drug-free periods (Cycles 2–6).
†The ALSFRS-R scale consists of 12 questions that evaluate the fine motor, gross motor, bulbar, and respiratory function of patients with ALS (speech, salivation, swallowing, handwriting, cutting food, dressing/hygiene, turning in bed, walking, climbing stairs, dyspnea, orthopnea, and respiratory insufficiency). Each item is scored from 0–4, with higher scores representing greater functional ability.

Dr. Anne Lortie, 2024 recipient

Dr. Lortie is recognized by her peers as a remarkable clinician, a fierce advocate, as well as an exceptional teacher and mentor. She has contributed immeasurably to the field of pediatric neurology and epilepsy through research, innovation, and the training of generations of pediatric neurologists. Throughout her career, she has worked to improve the care of children with epilepsy and neurodevelopmental diseases directly, and at the levels of health policy and administration. She leads with energy, devotion, and empathy. Her contributions earned her the 2021 Department of Pediatrics’ award for clinical excellence.

After completing medical school, and residency in pediatrics and neurology at the Universite de Montreal, Dr. Lortie pursued fellowship training in pediatric epilepsy at St-Vincent-de-Paul Hospital in Paris. She returned to Montreal with an expertise in epilepsy syndromes and evaluation for epilepsy surgery.

Dr. Lortie revolutionized the care of children with epilepsy at Sainte-Justine and in Quebec. She introduced the ketogenic diet and vagus nerve stimulation, and she initiated regular province-wide meetings to discuss complex cases. Throughout her career, Dr. Lortie has developed, integrated, and promoted the best clinical practices through clinical research, and local and international collaborations. She has authored 79 peer-reviewed scientific articles and 17 book chapters. She also co-authored the book "L’epilepsie chez l’enfant et l’adolescent" (2006, Editions Ste-Justine) which quickly became an essential reference for professionals, patients, and their families.

Her service to the profession both within our institution and at the provincial level is commendable. Serving as the Chief of Neurology at Sainte-Justine for 16 years (1999-2014), she is responsible for its exponential growth. Her ability to engage stakeholders, motivate team members, and develop new initiatives had a tangible impact on the quality of care provided to patients. Indeed, her contribution to numerous committees including the steering committee of the multidisciplinary neurodevelopment clinic (CIRENE), and the pediatric-to-adult transition committee exemplify her lasting effect on the care of patients at Sainte-Justine. Provincially, she served as an advisor and vice president of the executive committee of doctors, dentists, and pharmacists (CMDP) and in numerous roles on the board of the Association of Quebec Neurologists.

While her professional accomplishments might already qualify her for this award, Dr. Lortie’s true superpower is her training and mentorship. From the resident level up to junior (and even senior) staff, Dr. Lortie is a source of sound advice and generous support on all matters both professional and personal. She shares her clinical knowledge freely through invited speakerships, bedside teaching, and in the EEG lab. All who work with her learn from her exemplary professionalism, humanism, and compassion.

Of note, Dr. Lortie regularly becomes an important support system for international trainees during their time at SainteJustine and beyond. Indeed, there are pediatric neurologists now practicing in France, Lebanon, Italy, and those who remained in Canada consider Dr. Lortie family. In 2013, she was awarded the Guy Geoffroy Prize by pediatric neurology residents for her excellence in teaching and her support for educational initiatives. Additionally, since 2015, she has been actively involved in global education missions sharing her extensive knowledge with physicians in underserved regions including Vietnam, Haiti, Trinidad and Tobago, as well as in Guadeloupe and Martinique.

Dr. Lortie was nominated for this award by current, and past, colleagues and trainees in the Department of Neurology at CHU Sainte-Justine, and beyond.

In conclusion, they noted

“Dr. Lortie is a role model in the field of pediatric neurology, pediatrics, and neurology. We highlight her impact on the field of pediatric neurology through clinical research, academic service, initiation of programs, and the significant influence that she continues to have on trainees and faculty”.

Thank you and Congratulations Dr. Lortie!
PROVINCIAL AND PUBLIC DRUG PLAN FUNDING NOW AVAILABLE IN ALL PROVINCES

(criteria in addition to the indicated condition apply)!\(^2\)

Please refer to the respective provincial drug plans for full coverage details and restrictions.

AJOVY® IS BACKED BY THE AJOVY® TEVA SUPPORT SOLUTIONS® (AJOVY TSS) PATIENT SUPPORT PROGRAM!

1-833-302-0121  TSS@ajovycanada.ca

VISIT AJOVY.CA FOR MORE INFORMATION!

Please consult the Product Monograph at https://TevaCanada.com/en-Ajovy for important information relating to warnings, precautions, adverse reactions, conditions of clinical use, and dosing information that has not been discussed in this piece. The Product Monograph is also available by calling us at 1-833-302-0121.


AJOVY® is a registered trademark of Teva Canada Limited.

TEVA and the design version thereof are registered trademarks of Teva Pharmaceutical Industries Ltd. and are used under licence.

Teva Support Solutions® is a registered trademark of Teva Pharmaceutical Industries Ltd. and is used under licence.

© 2023 Teva Canada Innovation G.P. – S.E.N.C., Montreal, Quebec H2Z 1S8

MIG-CA-00293  April 2023
CONGRATULATIONS to the 2024 Society Prize Winners!

Expanded abstracts, submitted for a society prize, are judged on merit, by a board of faculty members in each society. Judges were impressed by the high quality of this years’ submissions.

Winners will be presenting their work at the CNSF Congress, during the Grand Rounds session on Friday, May 24th between 9:00 am and 12:00 noon.

The abstracts from these submissions, and all other CNSF accepted abstracts for the 2024 Congress, will be published within the CNSF Congress Abstract supplement within the Canadian Journal of Neurological Sciences (CJNS).

2024 CNS | Society Prize Winners

CNS André Barbeau Memorial Prize
Fatema AlZamanan
Obesity and multiple sclerosis severity: a Mendelian randomization study

CNS Francis McNaughton Memorial Prize
Seyed-Mohammad Fereshtehnejad
Distinct Longitudinal Brain Atrophy Trajectories in Parkinson’s Disease Clinical Subtypes: Insight Towards Precision Medicine

2024 CNSS | Society Prize Winners

CNSS K.G. McKenzie Memorial Prize for Basic Neuroscience Research
Alexander Landry
Establishing the utility of multi-platform liquid biopsy by integrating the CSF methylome and proteome in CNS malignancy

CNSS K.G. McKenzie Memorial Prize for Clinical Neuroscience Research
Justin Wang
Meningioma molecular classification predicts response to surgery and adjuvant radiotherapy: an integrated clinicomolecular analysis & prospective validation

2024 CACN | Society Prize Winner

CACN President’s Prize
Ronda Lun
Circadian Rhythm Influences Ischemic Core and Penumbra Volumes in Pediatric and Young Adult Populations – A Nationwide Cohort of 831 CT Perfusion scans

2024 CSNR | Society Prize Winner

CSNR Society Prize
Ian R. Macdonald
Standardized Approach to Direct First Pass Aspiration Technique for Endovascular Thrombectomy: Description and Initial Experience with CANADAPT

Congratulations

prepOSCE Program

Our most sought-after program for residents.

These sessions would not be possible without our supporters. Thank you to Biogen, Eisai, Lilly and Roche.
The Canadian Journal of Neurological Sciences (CJNS)

50 Years of the CJNS

The Canadian Journal of Neurological Sciences (CJNS) was founded in 1974 by Dr. Robert T. Ross of Winnipeg, two years after attending the inaugural Canadian Congress of Neurological Sciences in Banff in 1972. Dr. Ross’ vision was to create a forum to showcase the world class work being done by CNSF members in the clinical and basic neurosciences. In 1981, the CJNS became the official publication of the member societies of the CNSF and has remained so ever since.

The CJNS has established its reputation over the past half century as a highly respected, impactful, and multidisciplinary publication. Through a longstanding relationship with Cambridge University Press, the Journal publishes articles spanning the breadth of the neurological sciences, from basic laboratory and translational studies, to clinically themed papers across neurology, neurosurgery, child neurology, and neuroradiology, to original research and commentary in neuroethics.

New Journal Leadership

The CJNS announced its 7th ever Editor-in-Chief, Dr. Tejas Sankar, earlier in 2024. A clinician-scientist from the University of Alberta in Edmonton, Dr. Sankar is the first neurosurgeon to serve as Editor-in-Chief. He brings to the Journal a wealth of prior experience as an Associate Editor and well-published researcher, and is extremely enthusiastic about growing the CJNS and its impact. He is supported by a strong team of Associate Editors, Social Media Editors, an engaged Editorial Board, and volunteer peer reviewers from the CNSF membership and beyond.

Why you should publish with the CJNS

• The Journal is fully indexed in SCI (Clarivate), Scopus, Medline/PubMed, and Google Scholar.
• Our Impact Factor is now 3.2 and continues to climb, making the CJNS a top tier journal in the clinical neurosciences.
• We boast a rapid peer review process, with average time to first decision of less than 20 days.
• We have a strong and growing social media presence managed by dedicated social media editors, to ensure maximum reach and dissemination of your published articles. (@JournalCJNS, twitter.com/JournalCJNS, facebook.com/JournalCJNS).
• Newly accepted manuscripts are rapidly published online within a few days, in advance of their placement within an issue, and receive a “DOI” address that remains the same throughout the article life, making them easily citable.
• CJNS is a hybrid journal, offering authors the option to publish open access for a fee (article processing charge, or APC). CNSF membership offers a 50% discount on the standard APC of US $3255 (US $1628). CJNS is also a part of Cambridge’s robust Transformative Agreement program, meaning eligible authors can publish open access at no additional charge to them. Please visit the following online tool to check if your institution is part of a Transformative Agreement: cambridge.org/oa/waivers&discounts.
• CNSF members have full access to all CJNS articles by logging in on the CNSF website with CNSF member ID# and last name.

Visit the CJNS Journal: cnsf.org/journal

Editor-in-Chief:
Tejas Sankar

Associate Editors:
Philippe Huot
Mahendranath Moharir
Manas Sharma
Amy Yu

Social Media Editors:
Amit Persad
Aleksandra Mineyko

Please Follow, Like and Share us on:

twitter.com/JournalCJNS
facebook.com/JournalCJNS
CJNS Distinguished Reviewer of the Year 2023

Mark Keezer, MDCM, PhD

The Canadian Journal of Neurological Sciences (CJNS) sincerely appreciates the numerous, timely, and high-quality manuscript reviews completed by Dr. Keezer over the past year. This award is based on review statistics from 2023.

Mark Keezer MDCM PhD is a neurologist, Head of the epilepsy group, clinician researcher and epidemiologist at the Centre Hospitalier de l'Université de Montréal (CHUM). He is an Associate Professor (clinical) in the Department of Neurosciences and Adjunct Professor at the School of Public Health of the Université de Montréal.

Dr. Keezer’s research program is focused on the somatic comorbidities of epilepsy across the lifespan. Since 2016, Dr. Keezer is the director of the CHUM Tuberous Sclerosis Complex clinic for adults and more recently the University of Montreal Transition program for epilepsy (TÉCUM).

Dr. Keezer is a member of the editorial boards for Epilepsia and Neurology: Clinical Practice. He is a member of the clinical practice guidelines committee of the American Academy of Neurology as well as that of the International League Against Epilepsy.

Thank you Dr. Keezer. We appreciate your dedication and support of the CJNS.

cnsf.org/journal/reviewer-of-the-year

Presented in 2024

NEURO CAREERS

➤ Looking for a new career opportunity?
➤ Looking to advertise a position at your center?

Check out Neuro Careers!

Neuro Careers is an online, classified advertising resource on the CNSF website and linked on the CJNS page in Cambridge Core. Direct links to each classified ad are included in the CNSF members’ newsletter, the Neuro News.

Classified ads are posted online for two months, for less than $500. They open as a full-color PDF complete with graphics and company logos. In addition to our public web posting, we will post over our social media sites.

Neuro Careers is a great way to advertise job opportunities and fellowships to Neurologists, Neurosurgeons, Pediatric Neurologists, Neuropsychologists, Neuroradiologists and related health care professionals.

To find out more, contact Donna at donna-irvin@cnsf.org.

www.cnsf.org/neuro-careers
Life is elevated when more you shines through.

Enabling brighter moments drives us every day.

At Acadia, we’re building a leading neuroscience company to help elevate life. Through collaborations with colleagues, industry partners, healthcare professionals, advocates, and families, we’re searching for new ways to protect the core of what makes you uniquely you.

Learn more about our trailblazing breakthroughs in neuroscience at CA.Acadia.com.
Membership Committee

The issue of expanding membership numbers has never been as important as it is today. Every CNSF Society believes this objective is of the highest priority. Membership retention and growth is vital to the continued success and stability of each of our Societies and the increased numbers will result in higher revenues as well as increased interest and participation by registered delegates at the Congress, the CJNS journal and our various Committees. This makes us stronger and more relevant as individual Societies and as a Canadian Federation.

The CNSF membership committee is chaired by Jeanne Teitelbaum, and every CNSF Society has representation on this committee.

The primary goals of the Membership Committee are to:

- Increase the number of Full members in each Society.
- Increase the number of resident members in each Society.
- Expand the number of Societies to include related Neuroscience organizations whose membership is primarily Neurologists.
- Open membership to new categories of members (nurses, anesthetists, intensivists, pathologists etc.).
- Simplify the membership categories, review the costs of membership and potentially amalgamate certain categories.

The biggest and most important challenge that we need to address is how to increase our membership in each Society’s Full category. We need to build a strong organization whose membership is PRIMARILY neurologists, neurosurgeons and neuroradiologists.

Membership Committee Members are:

- Jeanne Teitelbaum, Committee Chair – CNS, CSC
- David Callen – CACN, CSCN
- Ian Fleetwood – CNS
- Carmen Parra-Farinas – CSNR
- Jessie Kulaga-Yoskovitz – CACN
- Dakota Peacock – CACN
- Katherine Tourigny – CNS
- Sam Molot-Toker – CNS
- Michael D Hill – CNS, CSC
- Emma Woo CNS
- Cathy Meng Fei Li CNS
- Darek Sokol-Randell – CNS
- Jacky Chow – CSNR
- Dan Morin – CNSF CEO
- Donna Irvin – CNSF Member Services

The CNSF Clinical Practice Guidelines Committee

Committee Purpose:

- The purpose of the Clinical Practice Guidelines Committee (CPGC) is to encourage and support the development and implementation of best-practice guidelines by other groups such as the Affiliate Societies and, if requested, to consider the endorsement of these guidelines.
- The CPGC will also assist in the dissemination of these guidelines within the membership of the CNSF, considering the applicability of specific guidelines to the Canadian practice context.
- The CPGC will also consider, for endorsement or comment, guidelines developed by organizations external to the CNSF if the guideline is deemed important and applicable to the Canadian practice context. Guideline review and endorsement will occur in accordance with procedures outlined in the CPGC processes document (separate from this document).

Committee Members include:

- Draga Jichici, Committee Chair – CNS
- Christian Stapf – CSC
- Donatella Tampieri – CSNR
- Jeanne Teitelbaum – CNS, CSC
- Joseph Megyesi – CNS
- JP Appendino – CACN, CSCN
- Kathleen Jacobs – CSNR
- Michael D Hill – CNS, CSC
- Steve Baker – CSCN
- Tejas Sankar – CNS
- Thilinie Rajapakse – CACN
- Dan Morin – CNSF CEO

Submit CPGs for Endorsement to:

- Dan Morin, CNSF CEO – dan-morin@cnsf.org
- cnsf.org/education/clinical-practice-guidelines
Advocacy Committee

Advocacy is an important part of the CNSF mission to support the neuroscience professions in Canada. The work of CNSF members and CNSF Member Societies is essential to the wellbeing of individuals affected by diseases, disorders, and injuries of the nervous system, therefore we must advocate with a strong and effective voice to support this work.

In an effort to advocate nationally the CNSF several years ago joined Neurological Health Charities of Canada (NHCC). The NHCC share our objectives and have formed a strong coalition in order to serve as one voice with a stronger sense of community and influence for positive change across Canada. For more information and to see the work of Neurological Health Charities Canada (NHCC) visit mybrainmatters.ca.

In 2022 CNSF President Michael D Hill reconstituted the CNSF’s Advocacy Committee. Each CNSF Society appointed its Advocacy Committee representatives.

Members Include:

- Michael D Hill – Committee Chair – CNS, CSC
- Dylan Blacquiere – CSC
- Elizabeth Donner – CACN
- Fraser Moore – CSCP
- Jai Shankar – CSNR
- Natarie Liu – CACN
- Michael Tso – CNSS
- Regan Cooley – CSC
- Stephanie DeGasperis – CACP
- Steve Baker – CSCP
- Linda Magnusson – CNS
- William Miller – CSNR
- Pat McDonald – CNSS
- Dan Morin – CNSF

Advocacy Committee’ Objectives and Activities going forward include:

- Influence public policy decisions on matters related to the CNSF Vision concerning the prevention, diagnosis, and management of neurological conditions.
- To advocate on behalf of the Neurosciences’ profession to policy makers or elected officials on those issues relevant to the neurosciences’ profession.
- To enhance public access to neuroscience services through advocacy initiatives.
- To advise and make recommendation to the CNSF Executive/Board on issues that merit involvement of the Federation in responding to any relevant issues.
- To support government relations strategies.
- To identify advocacy needs and resources.
- To communicate advocacy efforts to stakeholders.
- Work and/or partner with Affiliate and Associate Societies and other organizations to increase awareness of neurological conditions.
- To promote the Neurosciences’ profession to the public through education activities.
- Advocate for effective fundamental and applied research support.

It is important for us to advocate for our patients. If there are relevant issues that affect neurological care in Canada, I encourage you to bring them forward so that the CNSF can take a proactive role in advocacy.

Michael D Hill
President, CNSF
Chair, CNSF Advocacy Committee
CNSF Committees

CNSF Professional Development and Scientific Program Committees

www.cnsf.org/congress/about-congress/planning-committee

These Committees, with input from each CNSF Society, are essentially responsible for planning, developing, and implementing the Congress Program. These Committees are informed by feedback from previous Congress attendees through the individual session evaluations and overall Congress assessments, the CNSF Membership Survey and other related information and feedback that assisted in the development of the Program for 2024 in Toronto.

These (PDC-SPC) members spent time working collaboratively throughout the past year with the CNSF and all Societies to develop an excellent Program for 2024.

Thank you.

Scientific Program and Professional Development Committee members

- Joe Megyesi, CNSF SPC Chair, CNSS
- Gerald Pfeffer, CNSF SPC Vice Chair, CNS
- Michelle Mezei, CNSF SPC Vice Chair, CSCN
- Cian O’Kelly, CNSF PDC Chair, CNS
- Draga Jichici, CNS SPC
- Bastien Rioux, CNS SPC
- Tejas Sankar, CNSS SPC
- Kristen Ikeda, CSCN SPC
- Seyid Mirsattari, CSCN PDC
- David Callen, CACN SPC
- Hugh McMillan, CACN SPC
- Maryam Nouri, CACN PDC
- Laila Alshafai, CSNR SPC
- Jai Shankar, CSNR SPC
- Manohar Shroff, CNSF
- Christine Hawkes, CSC SPC
- Mahesh Kate, CSC SPC
- Ravinder Singh, CSC SPC
- Emma Woo, CNS Resident Rep
- Cathy Meng Fei Li, CNS Resident Rep
- Derek Sokol-Randell, CNS Jr Resident Rep
- Katherine Tourigny, CNSS Resident Rep
- Sam Molot-Toker, CNSS Jr Resident Rep
- Jessie Kulaga-Yoskovitz, CACN Resident Rep
- Dakota Peacock, CACN Jr Resident Rep
- Jacky Chow, CSNR Resident Rep
- Cecil Hahn, CNSF Vice President (CACN)
- Michael D Hill, CNSF President (CNS)
- Dan Morin, CNSF CEO

Virtual Exhibit Hall

The CNSF online Virtual Exhibit Hall (VEH) provides the opportunity for the current year of Sponsors and Exhibitors to showcase their company and provide links to their websites.

We are proud to showcase these CNSF Supporters, and their contributions to the Canadian Neurological community.

veh.cnsf.org
By the time clinical symptoms of Alzheimer’s disease appear, amyloid and tau pathology may have been present for decades.

References:

The images depicted contain models and are being used for illustrative purposes only.

© 2024 Eli Lilly and Company. All rights reserved. | PP-AD-CA-0028A EN
Built by the Canadian Pacific Railway, the Fairmont Royal York luxury Hotel opened June 11, 1929.

Introducing UPLIZNA®: the first and only approved therapy for NMOSD that targets CD19-expressing plasmablasts and plasma cells

Redefining B cell targeting with a glycoengineered design for optimal binding

UPLIZNA® (inebilizumab for injection) is indicated as monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorders who are anti-aquaporin-4 immunoglobulin G (AQP4-IgG) seropositive.

Treatment should be administered under the supervision of a qualified healthcare professional.

Visit the UPLIZNA® Product Monograph for more information relating to:
- Contraindications in patients with hypersensitivity to UPLIZNA®, history of life-threatening infusion reactions to UPLIZNA®, severe active infection, active or untreated latent tuberculosis, history of progressive multifocal leukoencephalopathy (PML), severely immunocompromised state, or active malignancy.
- Relevant warnings and precautions regarding infusion reactions, infections, hepatitis B screening, PML in patients treated with other B-cell-depleting antibodies, late neutropenia, immunizations, B-cell repletion time, monitoring of serum immunoglobulins, possible risk of malignancy, contraception use, pregnant and breastfeeding women, pediatrics, and geriatrics.
- Conditions of clinical use, adverse reactions, drug interactions, and dosing instructions.

* Clinical significance has not been established.

AQP4-IgG, aquaporin-4 immunoglobulin G; CD19, Cluster of Differentiation 19; NMOSD, neuromyelitis optica spectrum disorder.

References:
We asked two CNSF members for their views on work and life

Dr. Elizabeth Donner
MD, MSc, FRCPC – CACN Full Member

- Head, Division of Neurology, The Hospital for Sick Children
- Co-Lead, Garry Hurvitz Centre for Brain & Mental Health
- Bloorview Children’s Hospital Chair in Paediatric Neuroscience
- Professor of Paediatrics, Temerty Faculty of Medicine, University of Toronto

Q. Was there a defining moment that led you to choose the neurosciences as your career, and why?
A. During high school, I did a co-op placement at a preschool for children with neurodevelopmental disorders. For months I worked one-on-one with a boy with autism spectrum disorder. I was fascinated by his neurodiversity, and by our challenge to understand the complex interface between the brain and the mind. I went on to study neuropsychology and then medicine.

Another child’s story inspired my research career. While completing a neuropathology rotation during residency, I attended the post-mortem examination of a young child with epilepsy. I understood the heterogeneity of epilepsy; a spectrum encompassing developmentally typical, thriving children with infrequent seizures and children devastated by daily seizures and multiple comorbidities. However, the post-mortem that day did not demonstrate a neurodegenerative condition or acute respiratory condition, as I expected it would. The post-mortem did not demonstrate any cause of death at all. This was Sudden Unexpected Death in Epilepsy (SUDEP). I had never heard of such a thing – that a well child, living with epilepsy, could die suddenly and unexpectedly and no cause of death be found. I was shocked to learn about this risk to the children in my care. Since that day I have been advocating for SUDEP education and leading research to unravel the mystery of SUDEP.

Q. What was the greatest piece of advice you have received?
A. There is a poster hanging in my office, a gift from my mother, with a quote from Nellie McClung – “Never retract, never explain, never apologize; get things done and let them howl.”

McClung was a women’s rights advocate and suffragette in the 1920s, a member of the Famous Five who fought for Canadian women to be recognized as “persons” under the Constitution. While those words may lack nuance, they remind me that hard work, technology holds the promise to level the playing field for people with differing levels of ability. When we get the tech right, it can be a game changer.

Q. Which technology could you do without?
A. When it comes to technology, I think the old adage “everything in moderation” is best applied. While email, social media and smartphones are invading our every moment, we certainly can’t do without them. In my practice, something as simple as a parent capturing their child’s seizure on a smartphone has completely revolutionized how we care for children with epilepsy. Furthermore, the promise of technology and artificial intelligence to transform our lives for the better should not be forgotten. When applied well, technology holds the promise to level the playing field for people with differing levels of ability. When we get the tech right, it can be a game changer.

Q. What is your favourite book and why?
A. The Giving Tree. And truth be told, on a Friday night, I am probably watching a movie.

Q. How has your career in medicine created value in your life?
A. The greatest honour of my career is to be entrusted, by families, with the care of their children, to have their confidence and to accompany them on their journey. This kind of privilege is shared by few outside of healthcare. The value this experience brings to my professional life has been matched by my experiences working with families bereaved by epilepsy. They are some of the bravest people I have ever met and working alongside them has been motivating, inspiring and energizing.

Q. What advice would you give to someone aspiring to be successful?
A. There are so many roads to success, and I am still finding mine. Here are two pieces of advice that I think will point people in the right direction. Build a team around you, including friends, colleagues, mentors and mentees. Support your team with kindness and generosity so they can do their best work and you will all share in the benefits. Always be true to yourself and your beliefs. Everything is easier when our actions align with our values.
Introducing

The New Hizentra®
10 g/50 mL Pre-Filled Syringe

The first and only immunoglobulin delivered by pre-filled syringe – and now available in 10 g/50 mL

Hizentra®, Subcutaneous Immunoglobulin (Human) (SCIG), is indicated for:

• The treatment of patients with Primary Immune Deficiency (PID) and Secondary Immune Deficiency (SID) who require immune globulin replacement therapy.
• The treatment of patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment.

For more information, please consult the Product Monograph at https://labeling.cslbehring.ca/PM/CA/Hizentra/EN/Hizentra-Product-Monograph.pdf for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling 1-866-773-7721 ext. 2386.


© 2024 CSL Behring. All rights reserved.
Hizentra® is a registered trademark of CSLB GmbH.
Hizentra® is manufactured by CSL Behring AG and distributed by CSL Behring Canada Inc.
HIZ2024030398EN

Scan to visit hcp.cslbehring.ca for more information
We asked two CNSF members for their views on work and life

Dylan Blacquiere, MD MSc FRCPC (he/him)  
CNS and CSC Full Member

- Medical Director, Champlain Regional Stroke Network  
- Assistant Professor of Medicine (Neurology), University of Ottawa

Q. Was there a defining moment that led you to choose the neurosciences as your career, and why?
A. I’ve always wanted to be a doctor, but the plan was initially to become a family physician. Neurology wasn’t even on the radar until a pre-clerkship clinical session on the stroke unit at the Halifax Infirmary, working with Dr. Gord Gubitz. One couldn’t ask for a better teacher and mentor to begin with, so the stage was set, but the crystallizing moment was one patient, a woman who had had a left PCA stroke resulting in alexia without agraphia. She could write, but she couldn’t read. I was fascinated that such a thing could happen in the first place, let alone that there was a field of medicine devoted to trying to prevent and treat such events, and I was completely and irreversibly hooked. I haven’t ever looked back, and I still get excited when the time comes to give someone thrombolysis. If everything turns out just right, it still feels sometimes like the closest we can get to being a superhero, swooping in and saving the day when all seems lost.

Q. What was the greatest piece of advice you have received?
A. “The first job of every physician is to help to relieve the patient’s anxiety.” I’ve tried to have this guide my clinical interactions as a way to emphasize just how important communication is. I might not be able to solve every problem or alleviate every concern, but I can explain what I think is happening and what I’d like to do about it, and even if the underlying problem is still there, I’d like to think that advice helps me frame things so that people come out of every encounter with me with a little more understanding and a little less worry than before. Even if things are still grim or uncertain, I hope that having a little bit of the unknown addressed helps make things a little less worrisome.

Q. What do you do when you have downtime?
A. I was so unathletic as a kid that the fact that I’ve turned into a CrossFit gym rat still feels like an especially comic turn. I go to the gym, pick up heavy things, swing around on a bar and jump on boxes and come out feeling energized, refreshed, and enthusiastic. This year I finally got my first ring muscle-up after eight years of trying, I’m running my first Spartan race and my first Hyrox race, competing against a bunch of people probably half my age. I won’t win, but nothing boosts confidence like trying. I also like to cook; I’d describe myself as an adventurous amateur, nothing more, but there’s nothing more fun than cooking dinner for friends on a Saturday night and sharing a culinary experience that no one has ever tried before.

Q. What do you think of when you hear the words brain health?
A. There’s obviously cognitive health – memory, reason, emotional intelligence, empathy, understanding, planning and executive function – and it’s impossible to overestimate how important these are. It’s quite literally what makes us human. The ability to maintain those functions as we grow older, as we change, as the accumulated experiences and pitfalls of a human lifespan affect us and change us – that’s true brain health, and that’s what I hope to protect for myself, my loved ones, and my patients.

Q. What is your favorite book and why?
A. I have a lot. I love the novels of Robertson Davies – they just seem out of time, a distinguished and yet deeply funny and humanistic view of people with all their imaginations, flaws, and frailties. For fun, the absolutely chaotic works of Jasper Fforde and the His Dark Materials series by Phillip Pullman have always been favourites of mine as well. Both, in their way, share a deep love and respect for learning, inquisitiveness, inventiveness and individuality.

Q. Which technology could you do without?
A. I want to say social media, because I think it really has changed how we relate to each other and not entirely for the better. Anonymous sniping, abuse, narcissism, manipulation, and rage-farming have taken what could be a useful tool and turned it into a blight, for the most part; don’t get me started on the bad actors who take over platforms and turn them into pale cynical shadows of what they might have been. I would like to think it’s salvageable and that we can get rid of the bad aspects of social media in favour of a way to truly connect, engage and inform, but I think we have a long way to go.

Q. What one thing could everyone do to stay brain healthy?
A. Find some way to keep your body healthy – find an activity you enjoy, and then do it as often as you can. We know how physical activity helps with managing vascular risk factors, and we know that maintaining vascular health prevents the development of vascular cognitive impairment later in life, so eating healthy and staying physically active will pay so many dividends later on. But even beyond that, physical activity is one of the greatest stress relievers there is, and so there’s no better way I can think of for a great way to set yourself up for a quick burst of dopamine to face whatever the day brings.

Q. How has your career in medicine created value in your life?
A. I will admit that this can be hit or miss. Sometimes medicine can feel like a tremendously noble calling, and sometimes, especially the two a.m. consultation that probably didn’t need to be, it can feel more like a chore than a vocation. But at the end of the day, I get to do a job that helps me connect with people, have the potential to make a positive change, and leave the world a little bit better for somebody than it would have been had I not been there to help.

Q. What advice would you give to someone aspiring to be successful?
A. Don’t get too discouraged if the path you set down on, turns out to not be the way after all. It’s a very attractive notion to have your life planned out from start to finish – set a lofty goal, figure out what you need to do, and execute the steps you need to achieve it. There’s nothing wrong with that, and I admire people who do that, but that’s not the only way. Sometimes it’s okay to try a few things out and not be entirely sure of the way you’re going. With patience, and grace, and a little bit of luck, you’ll discover an amazing path that you perhaps hadn’t thought of before, and it can lead to a vast array of opportunities and options that you might not have considered. Keep an open mind, and an open heart, and sometimes it’s okay to let the tide bring you where you need to be.
Chez Eisai, tout ce que nous faisons est guidé par un principe simple : les patients et leurs familles sont notre priorité. Nous leur consacrons du temps. Nous les écoutons et nous nous informons sur leur vie, leurs désirs et leurs besoins les plus importants. C’est ce que nous appelons le “human health care” ou hhc, qui consiste à penser d’abord aux patients et à leurs familles et à améliorer les bienfaits que les soins de santé peuvent offrir.

Notre mission hhc est ce qui nous incite à découvrir des solutions et traitements novateurs qui contribuent à combler des besoins médicaux inassouvis pour la communauté que nous désirons servir.

hhc
human health care
A Century of Excellence in Neurosurgery: Celebrating 100 Years and Beyond

2024 marks the 100th anniversary of the Division of Neurosurgery at the University of Toronto’s Temerty Faculty of Medicine. Over the last century, we have evolved into one of the world’s largest and most prestigious neurosurgical training programs. From the outset, our mission has remained unchanged: to educate the most capable and talented medical students, grooming them to be the future leaders in neurosurgery.

The Division of Neurosurgery boasts a distinguished history of excellence, having produced leaders across North America and pioneers in every neurosurgical subspecialty. From groundbreaking brain, spine and peripheral nerve surgeries to innovative treatments incorporating functional neuroimaging, cutting edge technologies and advanced robotic techniques, the division has consistently set the gold standard in neurosurgery excellence in patient care, research, and training – paving the path for the next generation of trailblazers who will lead the field.

To coincide with the Canadian Neurological Sciences Federation (CNSF) Congress, the University of Toronto’s Division of Neurosurgery is hosting a scientific symposium and a gala celebration, featuring local, Canadian, and international speakers and guests. This is a wonderful opportunity for our community of neurosurgical leaders, learners, educators, and visionaries to come together, reflect on our history, and envision our future.

Please join the University of Toronto Temerty Faculty of Medicine, Division of Neurosurgery and our four esteemed teaching hospitals: St. Michael’s, Sunnybrook, Toronto Western, and the Hospital for Sick Children, in this once-in-a-century celebration.

University of Toronto event website uoftnsx100years.ca

University of Toronto social media: twitter.com/UofTNeuroSurge

CNSF Congress Abstracts

The CNSF Congress continues to be the premier Canadian meeting for the combined neurosciences, attracting Neurologists, Neurosurgeons, Pediatric Neurologists, Neurophysiologists, Neuroradiologists, Neuroscientists, and those in training.

Abstracts submitted to the CNSF Congress are reviewed by the Scientific Program Committee (SPC) and assigned to sessions, based on substantive grounds, to create a strong scientific program. Don’t miss these abstracts presented in the following formats.

Electronic Poster Stations

Abstracts designated for an e-poster, are created by the authors, and included on multiple, large screen, poster-viewing stations throughout the Congress meeting space. Posters are searchable by author, subject, or by poster number. All posters are loaded on all of the poster viewing stations and available for delegates to view at any time.

Poster Moderated Sessions

Tuesday, May 21 and Thursday, May 23 between 10:45 and 11:45 am

Want to find out more? Every e-poster is included in one of the poster-moderated sessions. These are separated and grouped by topic of interest. Authors are given a designated time to present their poster, concepts, methods, and research findings to the session attendees. Time is allotted for some questions and brief discussion.

On-site digital posters are also available in an online format for all delegates during the Congress from the 2024 event website and App. After the Congress, accessible through the CNSF ePoster Gallery, for members only for one year.

Society Mini-Platform Sessions

Friday, May 24, between 8:00 and 9:00 am

Mini-Platform sessions are separated by Society specific topics. Attend these brief oral abstract presentations on Friday morning before heading over to the Grand Rounds session.

Society Prize Winning Abstracts

Society Prize Winning abstracts will be presented during the Grand Rounds session: Friday, May 24, between 9:00 am and noon.

Authors that have been awarded a Society Prize for an “Expanded Abstract” submission, will present a platform presentation during the Grand Rounds session. There will be time allotted for some questions and brief discussion.

Canadian Journal of Neurological Sciences (CJNS), 2024 CNSF Congress Abstract Supplement.

All abstracts included at the CNSF Congress are published within the CJNS Abstract Supplement. cambridge.org/core/journals/canadian-journal-of-neurological-sciences

Consult the daily programs and include these presentations in your personal agenda.
At Eisai, everything we do is guided by a simple principle: Patients and their families come first. We spend time with them. We listen and we learn about their lives, their desires and their greatest needs. We call this human health care or hhc, giving first thoughts to patients and their families and helping increase the benefits health care provides.

Our hhc mission is what drives us to discover innovative solutions and therapies that help address unmet needs within the communities that we seek to serve.
2024 Grand Plenary Speakers

Wednesday, May 22, 8:00 am – noon
Featuring the following special guest lecturers!

CSNR – Terbrugge Lecture

DBS in the MRI Scanner: From Contra-Indication to New Method of Optimizing Treatment of Neurological Disease

Dr. Walter Kucharczyk, MD, FRCPC

Walter Kucharczyk was born, raised and educated in Toronto. He graduated from the University of Toronto’s Faculty of Medicine in 1979; after which he undertook specialty training in Radiology in Toronto, followed by subspecialty training in Neuroradiology and Magnetic Resonance Imaging at the University of California, San Francisco from 1984 to 1986. He returned to a faculty position at the University of Toronto in 1986, and became the inaugural Director of Magnetic Resonance Imaging at what was then the Toronto General Hospital. At the University, he became Professor and Chair of the Department of Medical Imaging in 1991, a position he has held until 2007. He is a senior member of the ASNR and past member of the AASNR Executive Committee. He is Past-President of the International Society of Magnetic Resonance in Medicine (ISMRM), the largest research and education group in the world (5000 members) devoted to developing and teaching magnetic resonance to doctors and scientists.

Dr. Kucharczyk is author of a book on MRI of the Central Nervous System. He has written over 200 scientific papers and has been invited to give more than 300 international lectures on every continent. He published several of the early papers on the design, operation, and treatment of novel Interventional MRI systems to guide surgical procedures, as well as research-based novel percutaneous and transcatheter MRI-guided treatment systems including several of the early papers on MR thermometry to monitor the effects of heat ablation on human cancer in vivo. Dr. Kucharczyk’s research has focused on developing and applying modern high-speed 3D imaging technologies for non-invasive and minimally invasive treatment. He has been awarded several multi-million dollar grants from Technology Ontario, the Canadian Foundation for Innovation, the Ontario Research and Development Challenge Fund (CFI), and the Leading Edge Fund of CFI. In a related program, he has also been PI on an ORDCF grant for the Ontario Consortium of Image Guided Therapy and Surgery (OCITS).

CNS – Richardson Lecture

Prosopagnosia: a classical condition in the modern era

Dr. Jason Barton, MD PhD

Jason Barton obtained his MD and completed neurology residency at the University of British Columbia. He was a fellow in neuro-ophthalmology at the University of Iowa and with Jim Sharpe at the University of Toronto, where he obtained his PhD. He was assistant and then associate professor of neurology at Harvard Medical School and director of neuro-ophthalmology at the Beth Israel Deaconess Medical Center from 1996 to 2004. Since 2004 he has been director of clinical neuro-ophthalmology at Vancouver General Hospital. He is currently professor, Canada Research Chair and Marianne Koerner Chair in Brain Diseases in neurology, ophthalmology and visual sciences, and psychology at the University of British Columbia.

He studies cortical processing of vision, in particular high-level object perception, such as face and word recognition, and the use of saccadic eye movements to explore cognitive control. He operates the website www.nerual-ophthalmology.ca, recognized by the American Academy of Neurology in 2011 as one of the best patient- and resident-education websites. He has received the Francis McNaughton Award from the Canadian Neurological Sciences Federation, the Young Investigator Award from the North American Neuro-ophthalmology Society, and the Norman Geschwind Award in Behavioural Neurology from the American Academy of Neurology.

CSCN Gloor Lecture

Algorithms and Artificial Intelligence in Epilepsy

Dr. Sándor Beniczky, MD PhD

Sándor Beniczky is a board-certified neurologist, clinical neurophysiologist and epileptologist. After completing medical school and the neurology residency at University of Szeged (Hungary) he completed a PhD in clinical neuroscience, and then moved to Denmark for his fellowship training in clinical neurophysiology and then epilepsy.

He is professor at Aarhus University Hospital (Denmark), the head of the Clinical Neurophysiology Department at the Danish Epilepsy Centre and honorary professor at the University of Szeged.

Professor Beniczky is currently the editor-in-chief of Epileptic Disorders, co-chair of the ILAE Neurotechnology Section, member of the Education Council, Congress Council, Big Data Council and Publication Council of the ILAE, past-chair of the joint EEG taskforce of the IFCN and ILAE, member of the IFCN Guidelines Committee.

The main research interest of Professor Beniczky is EEG and epilepsy, focusing on electromagnetic source imaging, seizure detection, automated and semi-automated analysis, artificial intelligence, standardisation and quality-assurance in clinical neurophysiology.

He has supervised 11 Ph.D. students. He is author of over 230 peer-reviewed papers and 23 book chapters.
VISIT VYEPTI.CA

**SIGNIFICANTLY REDUCED MONTHLY MIGRAINE DAYS**

**VS. PLACEBO IN PATIENTS WITH CHRONIC MIGRAINE**

*(Primary endpoint in the PROMISE-2 trial*: Reduction in mean MMD from baseline; Vyepti® 100 mg -7.7, placebo -5.6, p<0.0001; difference from placebo = -2; CI 95% [-2.9, -1.2])*1,2

†Vyepti® (eptinezumab for injection) is indicated for the prevention of migraine in adults who have at least 4 migraine days per month. Vyepti® should be prescribed by healthcare professionals experienced in the diagnosis and treatment of migraine.

---

**Chronic migraine — PROMISE-2 trial**

**Vyepti® 100 mg, weeks 1-12**

<table>
<thead>
<tr>
<th>Reduction in mean MMD from baseline</th>
<th>Vyepti® 100 mg</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>48% reduction</td>
<td>-7.7</td>
<td>-5.6</td>
</tr>
<tr>
<td>with Vyepti® (n=356)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>35% reduction</td>
<td></td>
<td></td>
</tr>
<tr>
<td>with placebo (n=366)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Proportion of patients achieving ≥75% reduction from baseline in monthly migraine days during the specified time frame.

**Clinical use:**
- No data are available in the pediatric population (<18 years of age). Therefore, Vyepti® is not authorized for pediatric use.
- The safety and efficacy of Vyepti® has not been established in geriatric patients (≥65 years of age). The clinical study program of Vyepti® did not include sufficient numbers of these patients to determine whether they respond differently from younger patients.

**Most serious warnings and precautions:**

- Hypersensitivity reactions: Serious hypersensitivity reactions, including angioedema, urticaria, rash and anaphylactic reactions have been reported with the CGRP-class products including Vyepti®. These reactions may develop within minutes of the infusion. If a serious hypersensitivity reaction occurs, administration of Vyepti® should be discontinued immediately and appropriate therapy initiated.

**Other relevant warnings and precautions:**
- Patients with cardiovascular diseases
- Patients with diabetes or morbid obesity
- Patients with hereditary fructose intolerance (HFI)
- Hepatic insufficiency
- Patients with HIV, Hepatitis B and C
- Patients with autoimmune disorder

**References:**
1. Vyepti® Product Monograph. Saint-Laurent, QC: Lundbeck Canada
Dr. Elaine Wirrell, MD PhD

Dr. Wirrell completed her medical school at the University of British Columbia, followed by a residency in Child Neurology at Dalhousie University in Canada. She is currently Professor and Chair of Child Neurology at Mayo Clinic in Rochester Minnesota. She has been integrally involved with the International Child Neurology Society for many years, serving as an ICNA Executive Board member since 2018, as Chair of the ICNA Research Committee from 2018-2022 and she is currently Co-Chair of the Bylaws and Constitution Committee. She served on the core Scientific Committee of the 2022 ICNC meeting in Antalya, Turkey and is Deputy Chair of the 2024 ICNC in Cape Town, South Africa.

Dr. Wirrell was the former Co-Chair of the Nosology and Definitions Task Force of the ILAE, and currently serves on both the Pediatrics and Surgical Therapies Commissions and the SNOMED Task Forces. She Co-Chairs the Pediatric Medical Therapies Task Force. She is Co-Editor-in-Chief of Epilepsy.com, the public education website for the Epilepsy Foundation of America.

Dr. Wirrell has a keen interest in Neurology Education and served as the Vice-Chair of the Neurology Examination Committee of the Royal College of Physicians and Surgeons of Canada from 2009-2014. She currently is the Program Director of the Child and Adolescent Neurology Residency at Mayo Clinic and served as Co-Chair of the Pellock Epilepsy Symposium, an educational program offered to all North American final year Child Neurology trainees through the Child Neurology Society from 2016-2023. Her research interests include optimizing care for children with Developmental and Epileptic Encephalopathies, epidemiology and co-morbidities of pediatric epilepsy and she has published over 270 peer-reviewed articles and numerous book chapters.

She has been the recipient of several awards including the AES Kiffin Penry award for Excellence in Epilepsy Care and the Mayo Clinic Distinguished Clinician award.

Dr. Edward Chang

Dr. Edward Chang is a neurosurgeon who treats adults with difficult-to-control epilepsy, brain tumors, trigeminal neuralgia, hemifacial spasm and movement disorders. He specializes in advanced brain mapping methods to preserve crucial areas for speech and motor functions in the brain. He also has extensive experience with implantable devices that stimulate specific nerves to relieve seizure, movement, pain and other disorders. He is the chair of the Department of Neurological Surgery.

Dr. Chang’s research focuses on the brain mechanisms for speech, movement and learning. He co-directs the Center for Neural Engineering and Prostheses, a collaborative enterprise of UCSF and the University of California, Berkeley. The center brings together experts in engineering, neurology and neurosurgery to develop state-of-the-art biomedical technology to restore function for patients with neurological disabilities such as paralysis and speech disorders.

Dr. Chang earned his medical degree at UCSF, where he also completed a residency in neurosurgery. He was honored with the Blavatnik National Laureate for Life Sciences in 2015. In 2020, he was elected to the National Academy of Medicine, an honor that recognizes outstanding achievements and service in the fields of medical sciences, health care and public health.

Dr. Moira Kapral, MD, MSc, FRCPC

Dr. Moira Kapral is a Professor of Medicine and Director of the Division of General Internal Medicine at the University of Toronto. She is a staff physician at the Toronto General Hospital/University Health Network, where she holds the Lillian Love Chair in Women’s Health. She is co-principal investigator of the Ontario Stroke Registry and she performs health services research with a focus on identifying and addressing inequities in stroke care and outcomes. She is a senior scientist at ICES and the Toronto General Hospital Research Institute and is cross-appointed to the Dalla Lana School of Public Health at the University of Toronto. She has received the Dr. J. Edgar Kenton III Award for Disparities Research from the American Stroke Association and the Distinguished Service Award from the Canadian Society of Internal Medicine.
# Exhibitor Listing

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Booth Number</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AbbVie</strong></td>
<td>503</td>
</tr>
<tr>
<td>At AbbVie, we combine advanced science, expertise and passion to solve serious health issues and have a remarkable impact on people’s lives. We’re a company that takes on the toughest health challenges. But we do more than just treat diseases. We’re meeting the health needs of people and societies around the globe.</td>
<td></td>
</tr>
<tr>
<td><strong>Acadia Pharmaceuticals Canada</strong></td>
<td>313</td>
</tr>
<tr>
<td>Bronze</td>
<td></td>
</tr>
<tr>
<td>Visit: <a href="http://ca.acadia.com">ca.acadia.com</a></td>
<td></td>
</tr>
<tr>
<td><strong>Alexion Pharma Canada</strong></td>
<td>204-206</td>
</tr>
<tr>
<td>Gold</td>
<td></td>
</tr>
<tr>
<td>Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the discovery, development and commercialization of life-changing therapies.</td>
<td></td>
</tr>
<tr>
<td><strong>Alnylam Pharmaceuticals Canada</strong></td>
<td>108-110</td>
</tr>
<tr>
<td>Alnylam is the leading RNAi therapeutics company. We believe our efforts have the potential to improve the lives of Canadian rare disease patients.</td>
<td></td>
</tr>
<tr>
<td><strong>Amicus Therapeutics</strong></td>
<td>113</td>
</tr>
<tr>
<td>Amicus Therapeutics is a global, patient-dedicated biotechnology company focused on developing and delivering high-quality medicines for people living with rare diseases.</td>
<td></td>
</tr>
<tr>
<td><strong>argenx Canada Inc.</strong></td>
<td>213</td>
</tr>
<tr>
<td>Gold</td>
<td></td>
</tr>
<tr>
<td>Where critical patient need meets breakthrough science – that’s where we are redefining immunology. argenx is a global immuno-oncology company committed to improving the lives of people suffering from severe autoimmune diseases.</td>
<td></td>
</tr>
<tr>
<td><strong>AstraZeneca</strong></td>
<td>207-209</td>
</tr>
<tr>
<td>Gold</td>
<td></td>
</tr>
<tr>
<td>AstraZeneca is a science-led biopharmaceutical company pushing the boundaries of science to deliver life-changing medicines in Rare Diseases, Oncology, and BioPharmaceuticals, including Cardiovascular, Renal &amp; Metabolism, and Respiratory &amp; Immunology.</td>
<td></td>
</tr>
<tr>
<td><strong>BC Neuroimmunology Laboratory Inc.</strong></td>
<td>201</td>
</tr>
<tr>
<td>BC Neuroimmunology specializes in providing best-in-class diagnostic tests with high-quality laboratory services in neuroimmunology and neurodegeneration throughout North America for clinical and research purposes, and human clinical trials.</td>
<td></td>
</tr>
<tr>
<td><strong>BioMarin Pharmaceutical</strong></td>
<td>400</td>
</tr>
<tr>
<td>BioMarin provides innovative therapeutics to patients with serious unmet medical needs.</td>
<td></td>
</tr>
<tr>
<td><strong>Carl ZEISS Canada</strong></td>
<td>307</td>
</tr>
<tr>
<td>Countless neurosurgeries are performed using visualization solutions from ZEISS. Designed to suit the greatest challenges of various neurosurgical procedures, ZEISS visualization systems support neurosurgeons to expand their boundaries of care.</td>
<td></td>
</tr>
<tr>
<td><strong>CSL Behring</strong></td>
<td>312</td>
</tr>
<tr>
<td>Bronze</td>
<td></td>
</tr>
<tr>
<td>A biotechnology company involved for more than a century with research and development related to severe and rare diseases, giving our support to patients with severe diseases.</td>
<td></td>
</tr>
<tr>
<td><strong>Eisai</strong></td>
<td>205</td>
</tr>
<tr>
<td>Platinum</td>
<td></td>
</tr>
<tr>
<td>Tokyo based, family-owned, and deeply entrepreneurial, Eisai focuses its efforts on areas of unmet patient needs. As a result, we currently have 18 compounds in clinical development across neurology and oncology. Each has a unique mechanism of action and are first to market compounds in their space.</td>
<td></td>
</tr>
<tr>
<td><strong>Eli Lilly Canada Inc.</strong></td>
<td>214</td>
</tr>
<tr>
<td>Silver</td>
<td></td>
</tr>
<tr>
<td>Established in 1938, Eli Lilly produced the world’s first commercially available insulin. Today, Lilly focuses on neurology, oncology, diabetes, autoimmunity, and pain.</td>
<td></td>
</tr>
<tr>
<td><strong>Galen Medical Ltd.</strong></td>
<td>511</td>
</tr>
<tr>
<td>Galen Medical is a Canadian supplier of innovative medical technologies in neurosurgery and spine. Visit our booth and try the latest Leica neurosurgery microscope – the future is ARveo 8!</td>
<td></td>
</tr>
<tr>
<td><strong>Hoffmann-La Roche Limited</strong></td>
<td>306-308</td>
</tr>
<tr>
<td>Gold</td>
<td></td>
</tr>
<tr>
<td>Roche is a leader in the research and development of pharmaceutical and diagnostic solutions that look beyond today’s horizons and make a profound difference in people’s lives.</td>
<td></td>
</tr>
<tr>
<td><strong>Horizon Therapeutics Canada (Amgen)</strong></td>
<td>504</td>
</tr>
<tr>
<td>Horizon, now part of Amgen, is a global biotechnology company focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare diseases.</td>
<td></td>
</tr>
<tr>
<td><strong>Integra LifeSciences (Codman Specialty Surgical)</strong></td>
<td>404-406-408</td>
</tr>
<tr>
<td>Gold</td>
<td></td>
</tr>
<tr>
<td>Integra LifeSciences, a world leader in medical technology, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions in neurosurgery, reconstructive and general surgery and orthopedic extremity surgery.</td>
<td></td>
</tr>
<tr>
<td><strong>Interior Health Authority</strong></td>
<td>409</td>
</tr>
<tr>
<td>Interior Health provides a vast array of specialty health care services. Experience unrivaled collegiality in stunning British Columbia.</td>
<td></td>
</tr>
</tbody>
</table>

Virtual Exhibit Hall: veh.cnsf.org
KEGO Corporation
KEGO Corporation is a manufacturer and distributor of medical equipment and supplies, specializing in products relevant to respiratory, sleep and neurodiagnostics.

Lundbeck Canada Inc.
As a subsidiary of H. Lundbeck A/S, a global pharmaceutical company specialized in brain diseases, we benefit from more than 70 years at the forefront of neuroscience research. We are tirelessly dedicated to restoring brain health, so every person can be their best.

MD Financial Management and Scotiabank Healthcare+
Together, MD Financial Management and Scotiabank provide a robust suite of comprehensive financial services tailored specifically to physicians’ needs and circumstances, including the uniquely co-created Scotiabank Healthcare+ Physician Banking Program.

Medexus Pharmaceuticals Inc.
Medexus Pharmaceuticals Inc. is an innovative specialty & rare disease pharmaceutical company focused on neuro-oncology, hematology, auto-immune diseases, and allergy.

Medtronic of Canada Ltd.
Through innovation and collaboration, Medtronic helps to improve the lives and health of millions of people each year. Learn more about our technology, services and solutions at Medtronic.ca.

MitoCanada
MitoCanada is Canada’s only registered health foundation dedicated to transforming the lives of individuals and families with mitochondrial disease by providing education and support, funding transformational research and raising awareness.

Mitsubishi Tanabe Pharma Canada
Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA) is focused on providing therapies for some of the most difficult-to-treat diseases. We strive to make a difference for those struggling with devastating illnesses.

Natus Medical Inc.
Natus provides leading solutions for the neurodiagnostic, neurosurgery, and neurocritical care markets.

NeuroSource Medical
We are a Canadian-owned neurodiagnostic distribution company made up of clinical professionals with combined expertise in EMG, EEG, IONM, SEEG and Sleep.

Novartis
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease.

Novus Medical Inc.
Novus is the exclusive Canadian representative for Cadwell neurology solutions.

Paladin Labs
With headquarters in Montréal, Canada, Paladin Labs Inc. is a leading specialty pharmaceutical company focused on acquiring or licensing emerging pharmaceuticals for the Canadian market.

Sanofi
Sanofi is a global biopharmaceutical company committed to healthcare solutions from prevention to treatment. We turn scientific discoveries into medicine to improve health.

Servier
Servier is a global pharmaceutical group (21,900 employees), governed by a Foundation. Our independence allows the freedom to pursue our vocation: our commitment to therapeutic progress to serve patient needs.

SRx Health Solutions
We are a leading provider of innovative, sustainable, and integrated healthcare solutions on a mission to enhance the wellness of Canadians through our all-encompassing end-to-end offerings.

Surgi-One Medical Technologies Inc.
Surgi-One is pleased to be featuring the following products at this year’s conference – Sugita T2 Aneurysm Clips and Appliers, Mizuho Micro Vascular Dopplers, Micro Surgical Instruments, Mizuho Neurosurgical Table, Ad-Tech Electrodes for Epilepsy Surgery, Thompson Spine Retractors, NSK Primado 2 Total Surgical System, DORO Cranial Stabilization and Retractor Systems, and SunOptics Surgical Headlights.

Teva Canada Innovation
At Teva, we care deeply about the wellbeing of the patients, caregivers and communities who rely on us. We serve 200 million people every day. From our role as a global leader in generic and brand-name medicines to the innovative solutions we create for our healthcare partners.

Vancouver Island Health Authority
Island Health provides comprehensive health care services to more than 850,000 people on Vancouver Island. Contact us to discuss our opportunities and the possibilities for your career, family and future!
Let’s go further. Together.

Nearly half of physicians in Canada already trust MD Financial Management and Scotiabank Healthcare+ to help them achieve financial well-being.¹ As a physician, your financial journey is unique – and the support you get should be too. Whether you just transitioned to practice or you’re a couple years in and have questions about the future of your career, we can provide advice and solutions to support you.

Scan to learn more about how we help physicians go further.

¹Based on Scotiabank and MD Financial Management physician market share as of February 2022.
Congress Sessions Supported by Industry

These sessions are an opportunity for registered delegates to attend specific topics of interest and are developed by the CNSF and “Industry”. A light lunch will be served. Pre-registration is required for each session through the Congress registration process.

Tuesday, May 21, 2024
12:00 noon – 1:30 pm • Lunch ’n Learns

1. Rare neurological diseases: Advancements in the treatment of gMG, NMOSD, and NF1

   Faculty: Mark Freedman, Mike Nicolle, Vijay Ramaswamy

   Review new advances and real-world management of 3 rare neurological diseases. Ravulizumab in the treatment of complement mediated diseases: gMG and NMOSD. Selumetinib in the treatment of patients with NF1 PN. Revisiting “the patient”, treatment goals, and meaningful benefits to patients.

   This program was developed by the CNSF and Alexion and was planned to achieve scientific integrity, objectivity and balance. It is an unaccredited learning activity and not eligible for MOC credits.

2. Navigating the Landscape of ATTR Amyloidosis

   Faculty: Michelle Mezei, Sami Khella, Diego Delgado

   This session will provide an overview of the ATTR amyloidosis disease spectrum, and discuss the diagnosis, treatment, and management of patients with ATTR. The session will help the audience understand the challenges related to the diagnosis and treatment of ATTR amyloidosis, and will provide fundamental knowledge of current and emerging therapeutic approaches.

   This event, chaired by Dr. Michelle Mezei (Division of Neurology, University of British Columbia), will highlight the importance of a multi-disciplinary approach to the management of ATTR patients, and will include a small panel of neurologists and a cardiologist to facilitate a comprehensive and multi-disciplinary discussion. Through a case-based approach, the panel will provide their perspective and discuss the importance of collaboration between neurologists and cardiologists in the management of ATTR amyloidosis.

   This program was developed by the CNSF and AstraZeneca and was planned to achieve scientific integrity, objectivity and balance. It is an unaccredited learning activity and not eligible for MOC credits.

3. Getting Ahead of Migraine: Multidisciplinary Strategies for Improving Patient Outcomes

   Faculty: William Kingston, Shawna Kelly

   The symposium aims to increase awareness of the disease burden of migraine on patients and to provide a summary of the natural disease course to recognize the importance of early intervention to reduce the risk of chronification. The faculty includes a neurologist and nurse practitioner specializing in headache, which will provide a complementary perspective on the management of migraine including patient counselling, monitoring of migraine symptoms and treatment response. Practical advice on novel therapies will also be provided.

   This program was developed by the CNSF and Lundbeck and was planned to achieve scientific integrity, objectivity and balance. It is an unaccredited learning activity and not eligible for MOC credits.

Wednesday, May 22, 2024
12:15 pm – 1:45 pm • Lunch ’n Learns

1. Redefining the extent of resection for glioblastoma and its impact on survival

   Chairs/Speakers: Dhany Charest, Moujahed Labidi, Randy D’Amico

   Gliomas are aggressive primary brain tumors and despite advances in treatment, prognostic remains poor. This course will review the new literature on the extent of resection and the impact on survival as well as other outcomes. The concept of (supra)maximal safe resection and new classification for the extent of resections will also be discussed. The new techniques, such as fluorescence-guided surgery, which complement other existing surgical tools allowing a higher degree of resection will also be reviewed. The American experience with these new techniques and perspective on how they fit with the other tools already available to maximize safe resection of brain tumors will be discussed.

   This program was developed by the CNSF and Medexus and was planned to achieve scientific integrity, objectivity and balance. It is an unaccredited learning activity and not eligible for MOC credits.
Gleolan™ (aminolevulinic acid hydrochloride) is indicated in patients with glioma World Health Organization (WHO) Grades III or IV (suspected on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery.

Consult the product monograph at https://pdf.hres.ca/dpd_pm/00057836.PDF for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available through our medical department. Call us at 1-877-633-3987.

2. Exploring FcRn blockade in gMG: A case-based approach

Faculty: Vera Bril, Oliver Blanchard, Nicholas Silvestri

Please join us for a case-based, interactive session as our expert faculty discusses evolving data on the role of neonatal Fc receptor (FcRn) inhibition in generalized myasthenia gravis (gMG). The faculty will present recent clinical evidence for efgartigimod alfa in the treatment of patients with AchR antibody-positive (AChRAb+) gMG. They will review key clinical data that help inform decisions around therapeutic options and discuss real-world patient cases and practical considerations for improving patient outcomes. Results of real-time audience polling will direct the flow and content of the session.

This program was developed by the CNSF and Argenx and was planned to achieve scientific integrity, objectivity and balance. It is an unaccredited learning activity and not eligible for MOC credits.

3. The Future is Now: A New Era in Alzheimer’s Disease Diagnosis and Treatment

Faculty: Alexandre Henri-Bhargava, Andrew Frank, Manish Joshi

This course will highlight the importance of early diagnosis in Alzheimer’s disease and the latest assessments to identify key factors that contribute to disease identification and progression. The speakers will appraise the efficacy and safety of disease modifying therapies (DMTs) and their role in slowing disease progression. This course will also explore management and monitoring strategies for disease modifying therapies, particularly imaging, to optimize patient outcomes and safety.

This program was developed by the CNSF and Eisai and was planned to achieve scientific integrity, objectivity and balance. It is an unaccredited learning activity and not eligible for MOC credits.

Thursday, May 23, 2024
12:00 noon – 1:30 pm • Lunch ’n Learns

1. Optimizing newborn screening and emerging clinical data in the evolving care of SMA

Faculty: Kathryn Selby, Hugh McMillan

The implementation of newborn screening for spinal muscular atrophy (SMA) has had a significant impact on clinical management of the disease. This course will provide details about how the steps involved with newborn screening have been optimized in different provinces and discuss how this impacts patient care and the multidisciplinary care teams. In addition, this course will review recent clinical trial results and highlight the important role of registry and real-world data in the clinical management of SMA.

This program was developed by the CNSF and Novartis and was planned to achieve scientific integrity, objectivity and balance. It is an unaccredited learning activity and not eligible for MOC credits.

2. Neuromuscular Diseases: Differential Diagnosis, Testing Options and reducing the diagnosis odyssey for patients

Faculty: Charles Kassardjian, Corey Bacher

This Lunch and Learn session will provide an in-depth exploration of Neuromuscular Diseases, focusing on the clinical manifestations and differential diagnosis considerations. Participants will learn more about the available testing options including enzymatic assays and genetic testing. This session will highlight the role of Neurologists in recognizing the signs and symptoms of neuromuscular disease, facilitating early diagnosis, and guiding patients to early disease treatment.

The course will provide (1) practical recommendations on the phenotypes of patients who should be considered for genetic testing, (2) some testing options available even to general neurologists, and (3) the value of appropriate diagnosis for the patient and managing neurologist through clinical cases.

This program was developed by the CNSF and Sano and was planned to achieve scientific integrity, objectivity and balance. It is an unaccredited learning activity and not eligible for MOC credits.

These programs are developed by the CNSF and Industry Partners and are planned to achieve scientific integrity, objectivity and balance. They are unaccredited learning activities and not eligible for MOC credits.
Codman’s got you covered.

The global leader in neurosurgery is your one-stop, comprehensive source for proven, market-leading neurosurgical solutions.
Don’t miss these 2024 Congress sessions!

HOT TOPICS

Wednesday, May 22, 2:00 pm to 4:00 pm

Garner some insights into the most current Hot Topics.

- **Hot Topics in Neurology:**
  Antibodies abound! Migraine, Multiple Sclerosis and Alzheimer’s Therapy Updates

- **Hot Topics in Neurosurgery:**
  Innovation and Entrepreneurship

- **Hot Topics in Clinical Neurophysiology:**
  Updates and Advances in EMG, EEG, MEG, and DBS

- **Hot Topics in Child Neurology:**
  A variety of cutting-edge topics

- **Hot Topics in Neuroradiology:**
  Imaging of Neurodegenerative Diseases

- **Hot Topics in Stroke:**
  Practice changing developments in stroke prevention, acute stroke therapies, and cerebral venous sinus thrombosis.

[2024cnsfcongress.eventscribe.net/SearchByBucket.asp?pfp=Track&bm=Hot%20Topics]

GRAND ROUNDS

Friday, May 24, 9:00 am to 12:00 noon

CNSF 2024 Congress features the Grand Rounds session on Friday morning

Time for a bit of fun and lively debate. Interesting cases are presented, and attendees have the opportunity to ask questions and suggest a diagnosis. What will the final outcomes reveal?

**2024 Society Prize Winners** will be in attendance and will present their work between the case presentations. Congratulations to this year’s winners.

[Lunch with the Exhibitors]

Hop over to the Exhibit Hall for a final visit with our exhibitors and a quick bite of lunch after the Grand Rounds session.

CSNR WEBINARS

The Canadian Society of Neuroradiology (CSNR) offers a series of accredited webinars covering a wide variety of Diagnostic Neuroradiology and Interventional Neuroradiology topics.

These sessions run throughout the year on a Tuesday afternoon at 3:00 pm Eastern time.

**Topics from the 2023-2024 season have included:**

- Pediatric Neuroradiology – Retinoblastoma
- Neurointerventional session – Novel spinal interventional techniques
- Head and Neck (orbit) – Neuroophthalmology for Radiologists
- Spectral CT in Neuroradiology
- Role of imaging in clinical management of MS patients

Emails are sent to the membership and [pre-registration](#) is required in advance of each session.

Recordings of previous webinars are available on the CSNR webpage: [cnsf.org/csnr/about-csnr](http://cnsf.org/csnr/about-csnr)
# 2024 CNSF Congress Schedule

Browse the full schedule and all the 2024 CNSF Congress program and event details. Visit [2024cnsfcongress.eventscribe.net](http://2024cnsfcongress.eventscribe.net) or scan the QR code.

<table>
<thead>
<tr>
<th>MONDAY MAY 20</th>
<th>TUESDAY MAY 21</th>
<th>WEDNESDAY MAY 22</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 – 11:30 am</td>
<td>8:00 – 10:30 am</td>
<td>7:00 – 8:00 am</td>
</tr>
<tr>
<td><strong>RESIDENTS’ COURSES</strong></td>
<td><strong>COURSES</strong></td>
<td><strong>CSCN EEG &amp; EMG SECTION MEETINGS</strong></td>
</tr>
<tr>
<td>• <strong>Neurology Residents’</strong>: Neuro-ophtalmology</td>
<td>• Parkinson’s Disease 101: From Diagnosis to Advanced Therapies</td>
<td>8:00 – 12:00 noon</td>
</tr>
<tr>
<td>• <strong>Neurosurgery Residents’</strong>: Neuroanatomy Radiology Review</td>
<td>• Updates and Innovations in Spine</td>
<td><strong>GRAND PLENARY</strong></td>
</tr>
<tr>
<td><strong>11:30 – 12:30 pm</strong></td>
<td>• Fetal Anatomy and Neuroradiography</td>
<td>• CNS Richardson Lecture: Jason Barton-Prospagnosia: a classical condition in the modern era</td>
</tr>
<tr>
<td><strong>RESIDENTS’ LUNCH</strong></td>
<td>• Autoimmunity in Neuromuscular diseases</td>
<td>• CACN Tibbles Lecture: Elaine Wirrell – Improving Outcome in Developmental and Epileptic Encephalopathies: Realistic Hope or Pipe Dream?</td>
</tr>
<tr>
<td><strong>12:30 – 3:00 pm</strong></td>
<td>• Stroke/ Vascular Neurosurgery Combined Educational Session</td>
<td>• CNSP Penfield Lecture: Edward Chang</td>
</tr>
<tr>
<td><strong>RESIDENTS’ COURSES</strong></td>
<td>• International Consortium on Meningiomas (ICOM) – Part 1</td>
<td>• CSC Sandra Black Lecture: Moira Kapral – Addressing Inequities in Stroke Care and Outcomes</td>
</tr>
<tr>
<td>• <strong>Neurology Residents’</strong>: Peripheral Paraclinical Investigations</td>
<td>• <strong>POSTER MODERATED SESSIONS</strong></td>
<td><strong>12:15 – 1:45 pm</strong></td>
</tr>
<tr>
<td>• <strong>Neurosurgery Residents’</strong>: Functional Neurosurgery</td>
<td><strong>LUNCH ‘N LEARNS</strong></td>
<td><strong>LUNCH ‘N LEARNS</strong></td>
</tr>
<tr>
<td><strong>3:00 – 6:30 pm</strong></td>
<td>• Rare neurological diseases: Advancements in the treatment of gMG, NMOSD, and NF1</td>
<td>• Redefining the extent of resection for glioblastoma and its impact on survival</td>
</tr>
<tr>
<td><strong>CNSF AGM, BOARD MEETING</strong></td>
<td>• Navigating the Landscape of ATTR Amyloidosis</td>
<td>• Exploring FcRn blockade in gMG: A case-based approach</td>
</tr>
<tr>
<td><strong>8:00 am – 12:15 pm</strong></td>
<td>• Getting Ahead of Migraine: Multidisciplinary Strategies for Improving Patient Outcomes</td>
<td>• The Future is Now: A New Era in Alzheimer’s Disease Diagnosis and Treatment</td>
</tr>
<tr>
<td><strong>10:45 – 11:45 am</strong></td>
<td><strong>1:00 – 4:15 pm</strong></td>
<td><strong>2:00 – 4:00 pm</strong></td>
</tr>
<tr>
<td><strong>POSTER MODERATED SESSIONS</strong></td>
<td><strong>COURSES</strong></td>
<td><strong>HOT TOPIC COURSES</strong></td>
</tr>
<tr>
<td><strong>12:00 – 1:30 pm</strong></td>
<td>• International Consortium on Meningiomas (ICOM) – Part 2</td>
<td>• Hot Topics in Neurology: Antibodies abound! Migraine, Multiple Sclerosis and Alzheimer’s Therapy Updates</td>
</tr>
<tr>
<td><strong>LUNCH ‘N LEARNS</strong></td>
<td><strong>1:45 – 4:15 pm</strong></td>
<td>• Hot Topics in Neurosurgery: Innovation and Entrepreneurship</td>
</tr>
<tr>
<td>• Rare neurological diseases: Advancements in the treatment of gMG, NMOSD, and NF1</td>
<td>• Demystifying Atypical Parkinsonian Syndromes: A Practical Approach</td>
<td>• Hot Topics in Neurophysiology: Updates and Advances in EMG, EEG, MEG, and DBS</td>
</tr>
<tr>
<td>• Navigating the Landscape of ATTR Amyloidosis</td>
<td>• Pediatric Neuro-ophthalmology</td>
<td>• Hot Topics in Pediatric Neurology</td>
</tr>
<tr>
<td>• Getting Ahead of Migraine: Multidisciplinary Strategies for Improving Patient Outcomes</td>
<td>• Going beyond EMG/NCS – Other diagnostic modalities in neuromuscular disorders</td>
<td>• Hot Topics in Neuroradiology: Imaging of Neurodegenerative Diseases</td>
</tr>
<tr>
<td><strong>4:15 – 5:15 pm</strong></td>
<td>• Roadmap to Epilepsy Surgery</td>
<td>• Hot Topics in Stroke</td>
</tr>
<tr>
<td><strong>SPC/PDC MEETING</strong></td>
<td>• Update on Alzheimer Disease and the utilities of fluid biomarkers in the differential diagnosis of dementia</td>
<td>4:15 pm</td>
</tr>
<tr>
<td><strong>5:15 – 6:45 pm</strong></td>
<td>• Update on Alzheimer Disease and the utilities of fluid biomarkers in the differential diagnosis of dementia</td>
<td>• CNS AGM</td>
</tr>
<tr>
<td><strong>CLINICAL CASE STUDIES (CCS)</strong></td>
<td>• Update on Alzheimer Disease and the utilities of fluid biomarkers in the differential diagnosis of dementia</td>
<td>• RCPSC – NEUROSURGERY SPECIALTY COMMITTEE MEETING</td>
</tr>
<tr>
<td>• Neuromuscular Case Discussion</td>
<td>• Update on Alzheimer Disease and the utilities of fluid biomarkers in the differential diagnosis of dementia</td>
<td><strong>4:15 – 6:30 pm</strong></td>
</tr>
<tr>
<td>• Video – EEG in epilepsy and other episodic events</td>
<td>• Neurovascular Case Discussion</td>
<td><strong>EXHIBITORS’ RECEPTION</strong></td>
</tr>
<tr>
<td>• Neuroimaging – Interesting Case Sessions</td>
<td>• Zebras and horses of unusual colours: the rare and curious cases of neuro-ophthalmology</td>
<td><strong>7:00 pm</strong></td>
</tr>
<tr>
<td>• Zebras and horses of unusual colours: the rare and curious cases of neuro-ophthalmology</td>
<td>• Neurosurgery Fireside Chat</td>
<td><strong>SOCIETY DINNERS:</strong></td>
</tr>
<tr>
<td><strong>7:00 – 9:00 pm</strong></td>
<td>• 7:00 – 9:00 pm</td>
<td>• CACN, CNSS, CSNR, CNS</td>
</tr>
<tr>
<td><strong>RESIDENTS’ AND FACULTY SOCIAL</strong></td>
<td><strong>SPC/PDC MEETING</strong></td>
<td><strong>WCN AGM</strong></td>
</tr>
<tr>
<td><strong>SPC/PDC MEETING</strong></td>
<td><strong>8:00 – 10:30 am</strong></td>
<td><strong>8:00 – 10:30 am</strong></td>
</tr>
<tr>
<td><strong>8:00 – 10:30 am</strong></td>
<td><strong>COURSES</strong></td>
<td><strong>CSCN EEG &amp; EMG SECTION MEETINGS</strong></td>
</tr>
<tr>
<td><strong>SOCIETY DINNERS:</strong></td>
<td>• Parkinson’s Disease 101: From Diagnosis to Advanced Therapies</td>
<td>8:00 – 12:00 noon</td>
</tr>
<tr>
<td><strong>7:00 pm</strong></td>
<td>• Updates and Innovations in Spine</td>
<td><strong>GRAND PLENARY</strong></td>
</tr>
<tr>
<td><strong>EXHIBITORS’ RECEPTION</strong></td>
<td>• Fetal Anatomy and Neuroradiography</td>
<td>• CNS Richardson Lecture: Jason Barton-Prospagnosia: a classical condition in the modern era</td>
</tr>
<tr>
<td><strong>4:15 – 6:30 pm</strong></td>
<td>• Autoimmunity in Neuromuscular diseases</td>
<td>• CACN Tibbles Lecture: Elaine Wirrell – Improving Outcome in Developmental and Epileptic Encephalopathies: Realistic Hope or Pipe Dream?</td>
</tr>
<tr>
<td><strong>EXHIBITORS’ RECEPTION</strong></td>
<td>• Stroke/ Vascular Neurosurgery Combined Educational Session</td>
<td>• CNSP Penfield Lecture: Edward Chang</td>
</tr>
<tr>
<td><strong>7:00 pm</strong></td>
<td>• International Consortium on Meningiomas (ICOM) – Part 1</td>
<td>• CSC Sandra Black Lecture: Moira Kapral – Addressing Inequities in Stroke Care and Outcomes</td>
</tr>
<tr>
<td><strong>SOCIETY DINNERS:</strong></td>
<td>• <strong>POSTER MODERATED SESSIONS</strong></td>
<td><strong>12:15 – 1:45 pm</strong></td>
</tr>
<tr>
<td><strong>7:00 pm</strong></td>
<td>• <strong>LUNCH ‘N LEARNS</strong></td>
<td><strong>LUNCH ‘N LEARNS</strong></td>
</tr>
<tr>
<td><strong>EXHIBITORS’ RECEPTION</strong></td>
<td>• Rare neurological diseases: Advancements in the treatment of gMG, NMOSD, and NF1</td>
<td>• Redefining the extent of resection for glioblastoma and its impact on survival</td>
</tr>
<tr>
<td><strong>7:00 pm</strong></td>
<td>• Navigating the Landscape of ATTR Amyloidosis</td>
<td>• Exploring FcRn blockade in gMG: A case-based approach</td>
</tr>
<tr>
<td><strong>SOCIETY DINNERS:</strong></td>
<td>• Getting Ahead of Migraine: Multidisciplinary Strategies for Improving Patient Outcomes</td>
<td>• The Future is Now: A New Era in Alzheimer’s Disease Diagnosis and Treatment</td>
</tr>
<tr>
<td><strong>7:00 pm</strong></td>
<td>• Update on Alzheimer Disease and the utilities of fluid biomarkers in the differential diagnosis of dementia</td>
<td><strong>2:00 – 4:00 pm</strong></td>
</tr>
<tr>
<td><strong>SOCIETY DINNERS:</strong></td>
<td>• Update on Alzheimer Disease and the utilities of fluid biomarkers in the differential diagnosis of dementia</td>
<td><strong>HOT TOPIC COURSES</strong></td>
</tr>
<tr>
<td><strong>7:00 pm</strong></td>
<td>• Update on Alzheimer Disease and the utilities of fluid biomarkers in the differential diagnosis of dementia</td>
<td>• Hot Topics in Neurology: Antibodies abound! Migraine, Multiple Sclerosis and Alzheimer’s Therapy Updates</td>
</tr>
<tr>
<td><strong>SOCIETY DINNERS:</strong></td>
<td>• Update on Alzheimer Disease and the utilities of fluid biomarkers in the differential diagnosis of dementia</td>
<td>• Hot Topics in Neurosurgery: Innovation and Entrepreneurship</td>
</tr>
<tr>
<td><strong>7:00 pm</strong></td>
<td>• Update on Alzheimer Disease and the utilities of fluid biomarkers in the differential diagnosis of dementia</td>
<td>• Hot Topics in Neurophysiology: Updates and Advances in EMG, EEG, MEG, and DBS</td>
</tr>
<tr>
<td><strong>SOCIETY DINNERS:</strong></td>
<td>• Update on Alzheimer Disease and the utilities of fluid biomarkers in the differential diagnosis of dementia</td>
<td>• Hot Topics in Pediatric Neurology</td>
</tr>
<tr>
<td><strong>7:00 pm</strong></td>
<td>• Update on Alzheimer Disease and the utilities of fluid biomarkers in the differential diagnosis of dementia</td>
<td>• Hot Topics in Neuroradiology: Imaging of Neurodegenerative Diseases</td>
</tr>
<tr>
<td><strong>SOCIETY DINNERS:</strong></td>
<td>• Update on Alzheimer Disease and the utilities of fluid biomarkers in the differential diagnosis of dementia</td>
<td><strong>4:15 pm</strong></td>
</tr>
<tr>
<td><strong>7:00 pm</strong></td>
<td>• Update on Alzheimer Disease and the utilities of fluid biomarkers in the differential diagnosis of dementia</td>
<td>• CNS AGM</td>
</tr>
<tr>
<td><strong>SOCIETY DINNERS:</strong></td>
<td>• Update on Alzheimer Disease and the utilities of fluid biomarkers in the differential diagnosis of dementia</td>
<td>• RCPSC – NEUROSURGERY SPECIALTY COMMITTEE MEETING</td>
</tr>
<tr>
<td><strong>7:00 pm</strong></td>
<td>• Update on Alzheimer Disease and the utilities of fluid biomarkers in the differential diagnosis of dementia</td>
<td><strong>4:15 – 6:30 pm</strong></td>
</tr>
<tr>
<td><strong>SOCIETY DINNERS:</strong></td>
<td>• Update on Alzheimer Disease and the utilities of fluid biomarkers in the differential diagnosis of dementia</td>
<td><strong>EXHIBITORS’ RECEPTION</strong></td>
</tr>
<tr>
<td><strong>7:00 pm</strong></td>
<td>• Update on Alzheimer Disease and the utilities of fluid biomarkers in the differential diagnosis of dementia</td>
<td><strong>7:00 pm</strong></td>
</tr>
<tr>
<td><strong>SOCIETY DINNERS:</strong></td>
<td>• Update on Alzheimer Disease and the utilities of fluid biomarkers in the differential diagnosis of dementia</td>
<td><strong>SOCIETY DINNERS:</strong></td>
</tr>
</tbody>
</table>

---

**Stay connected: Download the CNSF Congress App**

Access the most up-to-date information about the Congress, including schedules, session highlights, exhibitor info, maps and much more. Log in or create an account to favorite a presentation, access your personal schedule, take notes, or send feedback. Registered attendees have the added benefit of course material and evaluation surveys to claim CME credits.

Search for **CNSF Congress** in the App Store on your iPhone, iPad, or Android device. Download it for **free** and start planning your experience. **Watch for the 2024 CNSF event!**

Mobile App sponsored by argenx Canada, Inc.
2024 CNSF Congress Schedule

Browse the full schedule and all the 2024 CNSF Congress program and event details (as of April 18, 2024). Visit 2024cnsfcongress.eventscribe.net or scan the QR code:

THURSDAY MAY 23
6:30 – 8:00 am
JOURNAL BOARD MEETING

7:00 – 8:00 am
CSCN AGM

8:00 am – 12:00 pm
University of Toronto (OFF-SITE)
uoftnsx100years.ca
• Spine and Peripheral Nerve Special Topics
  Possible change to Wednesday, May 22

8:00 – 10:30 am
SOCIETY DAY
• CNS Day: Autoimmune Encephalitis
• CNSS Day: Neurosurgical Complications: Real-life Lessons & Consequences
• CSCN Day: Morbidity and Mortality in Epilepsy
• CACN Day: Pediatric Epilepsy – Part 1
• CSNR Day: Skull base
• CSC Day: Neuro-sonology Workshop

10:45 – 11:45 am
POSTER MODERATED SESSIONS

12:00 – 1:30 pm
LUNCH 'N LEARNs
• Optimizing newborn screening and emerging clinical data in the evolving care of SMA
• Neuromuscular Diseases: Differential Diagnosis, Testing Options and reducing the diagnosis odyssey for patients

12:00 – 1:30 pm
LUNCH IN THE EXHIBIT HALL

1:45 – 4:15 pm
SOCIETY DAY
• CNS Day: Neurology and Pregnancy
• CNS Day: Multiple Sclerosis: A practical approach to high efficacy disease modifying therapies
• CNSS Day: Schwannoma / Neurofibroma
• CSCN Day: EMG/NCS interpretation through clinical cases
• CACN Day: Pediatric Epilepsy – Part 2
• CSNR Day: Evidence based practice in Interventional Neuroradiology
• CSC Day: Resident Review Workshop

4:30 – 6:00 pm
CACN AGM
CNSS AGM
CSNR AGM

FRIDAY MAY 24
8:00 – 9:00 am
SOCIETY MINI-PLATFORM

9:00 – 12:00 pm
GRAND ROUNDS
• Society Prize Winning Abstracts and Interactive Case Presentations
• CNS
• CSCN
• CACN
• CSNR
• CSC

12:00 – 1:00 pm
• LUNCH IN EXHIBIT HALL

FRIDAY MAY 24

12:00 – 1:00 pm
LUNCH IN EXHIBIT HALL

1:30 – 3:15 pm
• Functional Neurosurgery

3:30 – 5:00 pm
• NeuroOncology Neurosurgery

6:00 – 10:00 pm
TORONTO 100 ANNIVERSARY GALA DINNER
• Celebrating 100 Years of Neurosurgery Excellence

SATURDAY MAY 25

UofT NSX 100 YEARS COURSES

1:30 – 3:15 pm
• Functional Neurosurgery

3:30 – 5:00 pm
• NeuroOncology Neurosurgery

6:00 – 10:00 pm
TORONTO 100 ANNIVERSARY GALA DINNER
• Celebrating 100 Years of Neurosurgery Excellence

SUNDAY MAY 26

UofT NSX 100 YEARS COURSES

2:30 – 4:00 pm
• Women and Diversity in Leadership Neurosurgery

Visit our 2024 Exhibit Hall to view some of the latest technologies to assist in your practice

These exhibitors are here to see you, and they are proud to demonstrate the science behind their medical devices and the efficacy of their products. Drop by the Exhibit Hall to enjoy some conversation and coffee while you take a look around. Lunch is served at 12:00 pm Thursday and Friday.

Wednesday
4:15 pm – 6:30 pm Exhibitor’s Reception

Thursday
10:00 am – 5:30 pm

Friday
10:00 am – 1:00 pm

Thank you for supporting our industry partners as they support us.
Thank you to our 2024 Major Supporters

**PLATINUM**

- Eisai

**GOLD**

- Alexion®
- AstraZeneca Rare Disease
- argenx
- INTEGRA.
- MEDXUS PHARMA
- Lundbeck
- Novartis
- Roche
- sanofi

**SILVER**

- Biogen
- Lilly
- MD Financial Management
- Scotiabank Healthcare+

**BRONZE**

- ACADIA
- CSL Behring
- Mitsubishi Tanabe Pharma Canada
- Stryker
- Teva

**SUPPORTER**

- paladin